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Hematopoiesis is a critical system that provides blood cells necessary for nutrient
and oxygen transfer throughout an organism and for protection from harmful agents. It is
maintained throughout life by the hematopoietic stem cells (HSCs) that reside within the
bone marrow (BM) and are responsible for providing billions of new cells each day. HSCs
maintain a careful balance between a quiescent state, that sustains the integrity of the
stem cells, and a proliferative state, that provides new cells to replenish those that undergo
apoptosis. Hematopoiesis is regulated by a variety of intrinsic pathways and extrinsic
signals such as cytokine signaling, transcription factor expression, and post-translational
regulation, including the ubiquitin proteasome system (UPS). Dysregulation of these
pathways can lead to hematopoietic failure or malignant transformation. The key
components of the UPS are the E3 ubiquitin ligases that determine which proteins are
degraded within the cell.
We identified FBXO9, the substrate recognition component of the Skp1-Cul1-Fbox E3 ligase complex, as an important regulator of normal and malignant hematopoiesis.
To facilitate study of FBXO9 in HSC maintenance and transformation, we engineered the
first tissue specific conditional Fbxo9 knockout mouse model. Analysis of BM and blood
derived from Fbxo9-/- mice revealed that its loss does not overtly impact HSC function and
very few alterations were seen in normal hematopoiesis. A mass spectrometry analysis of
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Fbxo9-/- BM under conditions of myeloablative stress revealed that knockout of this E3
ligase resulted in the differential expression of proteins involved in metabolism, a process
important to maintaining the balance between quiescence and differentiation and in
preventing malignant transformation.
When systems important for maintaining HSCs are dysregulated, it often results in
the formation of malignancies such as acute myeloid leukemia (AML). AML is the most
common form of acute leukemia and second most common form of childhood leukemia.
Analysis of adult and pediatric patient datasets revealed low Fbxo9 expression across all
AML subtypes when compared to other F-box proteins in the SCF family. Furthermore,
patients with inv(16)/t(16;16) have particularly low expression even when compared to
other AML subtypes. Utilizing our Fbxo9 knockout mouse model, we observed that loss of
Fbxo9 concurrent with expression of the inv(16) fusion protein, CBFB-SMMHC, led to the
rapid onset and progression of AML. Alone, CBFB-SMMHC expression results in a block
in myeloid differentiation that eventually gives rise to AML but when expression of the
fusion protein is combined with loss of Fbxo9, the resulting AML has a more aggressive
phenotype with high frequency of immature blasts in the BM and peripheral organs. A
mass spectrometry analysis of Fbxo9-/- inv(16) AML tumor cells revealed that loss of
Fbxo9 leads to an increase in proteasome component expression and proteasome
activity. Furthermore, loss of this E3 ligase resulted in greater sensitivity to proteasome
inhibition treatment. Taken together, our studies identify FBXO9 as a novel tumor
suppressor of AML and provide evidence that inhibiting the proteasome in patients with
low FBXO9 expression could prove more efficacious in treating the disease.
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CHAPTER 1
INTRODUCTION: HEMATOPOIETIC REGULATION
Regulation of Hematopoiesis
Hematopoiesis is the process through which blood cells are created and
replenished within an organism. Mature hematopoietic cells, including red blood cells
(RBCs) and white blood cells (WBCs), are relatively short-lived and must constantly be
replenished by the hematopoietic stem and progenitor cells (HSPCs) in order to maintain
homeostasis throughout life.1 Hematopoiesis largely takes place in the bone marrow (BM)
of adults and is one of the most well-studied adult stem cell-reliant processes. HSPCs are
responsible for generating a vast number of cells in the hematopoietic system with
functions such as oxygen transportation, host defense, and injury repair. The
hematopoietic stem cells (HSCs) and hematopoietic progenitor cells (HPCs) reside in
highly organized and distinct niches that influence HSPC biology and function.
Within the BM, there are two discrete niches in which HSCs can reside: the
endosteal niche and the perivascular niche.2 Each niche is composed of a different set of
cells with distinct biological functions that affect HSC quiescence and cycling. The
endosteal niche is primarily composed of osteolineage cells that reside at the bone-BM
interface. Though HSCs do not directly associate with osteoblasts and osteoclasts,
paracrine signaling of growth factors, chemokines, and other factors secreted by these
cells promote HSC quiescence.3 In particular, long-term hematopoietic stem cells (LTHSCs) tend to reside in the endosteal niche where they remain largely quiescent to
preserve the integrity of the HSC pool.2 Outside of the endosteal niche, a complex vascular
network permeates the BM to supply oxygen and nutrients and to allow the newly
differentiated hematopoietic cells to enter the blood stream. Areas within the BM near the
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blood vessels are known as the perivascular niche. Cells predominant in this niche include
reticulocytes, endothelial cells, and mesenchymal cells that all secrete factors important
for HSC maintenance such as CXCL12 and stem cell factor.4 HSCs found in the
perivascular niche tend to be the faster cycling short-term stem cells (ST-HSCs) that play
a more active role in hematopoietic cell generation.5
Maintenance of the hematopoietic populations is a tightly regulated process that
balances quiescence, self-renewal, and differentiation. When the regulation of this system
fails and errors are introduced, it can lead to the development of malignancies. One of the
main hematologic malignancies is leukemia, a cancer that develops within and affects the
blood and BM.
Leukemia
There are four common forms of leukemia, two of which are chronic and two of
which are acute (leukemias summarized in Table 1). These malignancies cause abnormal
proliferation of a specific type of cell within the BM that results in a loss of normal
hematopoiesis. Leukemias typically arise from cytogenetic alterations such as inversions,
translocations, deletions, or aneuploidy. Acute lymphocytic leukemia (ALL) most
commonly presents in pediatric patients who have a cure rate of about 90% while adults
have a much higher rate of relapse or refractory disease.6 ALL tends to more commonly
result from hyper- or hypoploidy than the other leukemias.7 ALL can have characteristics
of either the B or T cell lineage and each arises from a distinct set of cytogenetic changes
or mutations.8 Acute myeloid leukemia (AML), on the other hand, stems from
overproduction of one of the myeloid lineages. AML is the most commonly diagnosed
leukemia, has the lowest five year survival, and results in the majority of the leukemiarelated deaths.9 Along with AML, chronic lymphocytic leukemia (CLL) is one of the more
common forms and is characterized by the accumulation of B cells with a specific

3
immunophenotype distinct from normal B cells (Iglo, CD5, CD19+, and CD23+).10 CLL is
often recognized by its characteristic chromosomal deletions that affect clinical outcome:
11q22, 11q23, 13q14, or 17p13.11 Patients with this type of leukemia have variable
diagnoses with some being extremely indolent while others progress more rapidly. The
myeloid counterpart to CLL, chronic myeloid leukemia (CML), has perhaps the most
notable cancer success story to date. Most CML cases are driven by the
t(9;22)(q34;q11.2) translocation that results in the BCR-ABL fusion protein. This
constitutively active tyrosine kinase promotes excessive proliferation of myeloid cells and
breakthrough therapies with tyrosine kinase inhibitors have drastically improved clinical
outcome.12,13
The effective use of targeted tyrosine kinase inhibitors in CML illustrates the
importance of studying normal and malignant hematopoiesis to understand how normal
regulation should occur and what types of alterations drive leukemia initiation.
Hematopoietic cell preservation, differentiation, and prevention of malignancy are
controlled by a variety of intrinsic signaling pathways and extrinsic networks. The
decisions to remain dormant or enter the cell cycle and differentiate are thought to be
partially stochastic and partially controlled by cellular signals. Some of these cues are cellextrinsic and originate from the microenvironment while others are cell-autonomous. They
include cytokine signaling, transcriptional regulation, and post-translational regulation.
Regulation by cytokines
Hematopoietic niches provide the necessary conditions for HSC maintenance,
self-renewal, and differentiation primarily through secretion or membrane-bound
expression of proteins that engage receptors on the HSC surface. Proteins of this type are
known as hematopoietic growth factors, or cytokines, and are one of the main forms of
cell extrinsic regulation. Debate about the role of cytokines in HSC fate has centered
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around the question of whether cytokines act in a permissive or instructive fashion. Recent
work has shifted the understanding to one in which hematopoiesis is predominantly,
though not exclusively, controlled by the instructive expression of cytokines that dictate
cell fate.14 Each cytokine binds to either a homo- or heterodimeric cell surface receptor to
initiate a unique ligand-directed signaling pathway.15 Over 50 hematopoietic cytokines
exist and can be subdivided into colony-stimulating factors (CSF), interleukins (ILs), or
other cytokines.
Colony-stimulating factors
As some of the first cytokines to be discovered, this class is named for its ability to
instigate growth of hematopoietic colonies in a semisolid matrix.16 CSFs are secreted
glycoproteins that stimulate HSCs to give rise to a specific cell or set of cells. Alone,
granulocyte/macrophage colony-stimulating factor (GM-CSF) and multipotential colonystimulating factor (multi-CSF, more commonly known as IL-3) give rise to a mixture of
myeloid cells. Granulocyte colony-stimulating factor (G-CSF) and macrophage colonystimulating factor (M-CSF) promote the irreversible commitment to a single cell type and
either become a granulocyte or macrophage, respectively.17 CSF function is important in
specifying differentiation of HSCs but the CSF-CSF receptor interactions also influence
mature myeloid cells to activate them and instigate pro-survival mechanisms.18 Though
short-lived, these glycoproteins have a potent effect on hematopoiesis and are capable of
affecting change at picomolar concentrations.19 G-CSF and M-CSF seem to have the most
responsibility for myeloid cell production whereas loss of GM-CSF or IL-3 has little effect
on cell production but a greater effect on cell maturation and mature cell activity.20 CSF
cytokines are not solely responsible for directing differentiation but work together with
other cytokines like ILs.
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Interleukins
The second family of glycoprotein cytokines that exert influence on hematopoiesis
are the IL cytokines. Over 50 ILs and IL-like proteins have been identified, though not all
exert critical functions on HSC development and maturation. Some of the more influential
ILs include ILs-1 through 7. Of these, some play a more active role in lymphoid
commitment and maturation while others work primarily in the myeloid branch. The first
one involved in lymphoid commitment and development is IL-7. This cytokine influences
HSCs to progress down the differentiation pathway toward lymphoid commitment. 21 The
presence of IL-7 receptor (IL-7R) is a key cell surface marker that distinguishes lymphoid
progenitor cells and the IL-7R+ cells can further commit to become either B or T
lymphocytes. IL-2 is the principle growth factor responsible for T lymphoid commitment
and maturation. This cytokine dually induces the response of T effector cells and maintains
regulatory T cells to broadly influence the T lymphoid branch.22 IL-4, which is produced by
T cells, promotes the maturation of B lymphocytes specifically by instigating class switch
recombination and somatic hypermutation to produce fully developed antibodies and B
cells.23 IL-6 is known for its pleiotropic function in hematopoiesis. Some of its more wellcharacterized functions include prompting the differentiation of active B cells into antibody
producing plasma cells, promoting the maturation of CD4+ and CD8+ T cells into their fully
functional T helper or cytotoxic T cell counterparts, and aiding in the completion of
thrombopoiesis.24-27 IL-6 exemplifies the ability of a single cytokine to manipulate multiple
branches at varying stages of hematopoietic differentiation, influencing both lymphoid and
myeloid cells. Others have a more direct role in myeloid cell processes.
IL-1 was the first interleukin identified and is known for its proinflammatory function,
often working in harmony with tumor necrosis factor alpha (TNFα), a second inflammatory
cytokine. The primary role of IL-1 is to mount a rapid response to infection, instigating
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myeloid cell activation to increase the innate immune response.28 More recently, IL-1 was
found to spur HSC differentiation along the myeloid pathway while subsequently blocking
lymphopoiesis in response to myeloablation or transplantation.29 IL-3 represents the CSF
family, though it has a broad range of activity across multiple hematopoietic lineages and
has even been shown to play an integral role in embryonic HSC development.30 This
cytokine is produced and activated by CD4+ and CD8+ T cells in response to invasion and
is responsible for evoking a greater immune response.31 IL-5 is involved in eosinophil
activation, proliferation, and migration to sites of host-invasion.32,33 The presence of IL-5
in the blood stream is critical for the immediate response of this branch of innate immunity
in response to foreign material.
Other hematopoietic cytokines
The history of cytokine study dates to the early and mid-1900s with the initial
discovery of erythropoietin (EPO), the cytokine required for the production of RBCs.34 EPO
is distinct from CSFs and ILs in that it is almost solely and exclusively responsible for
erythropoiesis whereas the previously described cytokines typically affect multiple
lineages and work in parallel to other cytokines. The production of EPO in the kidneys and
liver is of vital importance and both an overproduction and underproduction of erythrocytes
can result in the development of detrimental blood disorders.35 A second hematopoietic
growth factor with a single, primary function is thrombopoietin (TPO). Researchers long
speculated that a compound similar to EPO was responsible for instigating thrombopoiesis
and the eventual discovery of the receptor c-MPL and its ligand TPO proved this theory
correct.36 TPO exerts its influence throughout the entire process of megakaryopoiesis,
from development of immature megakaryocytes to the final maturation stage of platelet
formation. Together with CSFs and ILs, these two cytokines comprise the main classes of
hematopoietic growth factors. Their function, however, is not limited to normal
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hematopoiesis, but they have also been shown to play a role in promoting and/or
combating malignancies.
Cytokines in malignancy and disease
Due to their critical role in promoting HSC cycling and blood cell differentiation,
cytokines have been used to treat diseases and conditions affecting blood and immune
cells. Treatment with EPO has been extremely effective in combating anemia, particularly
when associated with renal disease.37 In cancer treatment, some of the most detrimental
side-effects are those affecting various hematopoietic cells and patients often suffer from
treatment-induced anemia, thrombocytopenia, neutropenia, and other cytopenias.
Neutropenia was initially one of the primary dose-limiting side-effects for cancer treatment
and, though it is still a problem today, much of the problem has been allayed due to the
use of G-CSF and GM-CSF following myeloablative chemotherapy to aid in BM
recovery.38 Use of these cytokines effectively stimulates hematopoietic recovery and it is
as yet unknown if overuse promotes the development of cancer. In mice, prolonged CSF
elevation led to severe and even lethal hyperplasia but not to the point of tumorigenesis.39
While leukemogenesis due to CSF treatment seems unlikely, the possibility of therapyrelated leukemia development due to overexposure cannot be ruled out. Though not yet
shown to have a cancer-initiating role through the use as post-chemotherapy treatment,
cytokines have long been known to assist in tumorigenesis through overactive
inflammation. The successful implementation of cytokine treatment to assuage debilitating
side-effects has shown the advantage to understanding cytokine regulation of
hematopoiesis.
A second application of cytokines with respect to cancer is their use in activating
the immune system to eliminate tumor cells. One of the leading causes of cancer-related
death is the presence of metastatic lesions, some of which remain undetectable for years
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even when patients achieve a complete remission. The possible mobilization of immune
cells against tumors presents an efficient and effective method of completely eradicating
tumor cells and preventing future outgrowth. Chimeric antigen receptor modified T cells
(CAR-T) have been effectively used in the treatment of B-ALL. Though this system does
not utilize cytokines to activate the immune system, it demonstrates the power the immune
system has in fighting off disease, with B-ALL complete remission rates up to 94%.40 CART cells represent only one small branch of immunity while a true immunotherapy would
make use of every aspect of the immune system. Cytokine treatment has the potential to
elicit a full immune response and attempts have been made to enhance the host immunity
against certain cancers.20 With respect to hematopoietic malignancies, cytokines are
capable of instigating cellular maturation and terminal differentiation of tumor cells to
eliminate tumor cells from the blood and lymphatic systems.41,42 Though cytokines present
great potential for combating malignancies, their activation can be a double-edged sword
and has been found to act in a tumor-supportive fashion.
Roughly 25% of cancer-causing factors are related to infection and inflammation.43
Inflammatory cytokines such as TNFα, IL-1, and even GM-CSF cause alterations in
cellular signaling and induce cellular stress. Prolonged upregulation of inflammatory and
stress-response pathways leads to DNA damage and subsequent cancer development.44
The tumor microenvironments of some cancer types, most notably pancreatic ductal
adenocarcinoma, notoriously have high levels of immune cell infiltration yet these cells fail
to mount a response to the tumors. In fact, the presence of inflammatory cytokines and
tumor associated macrophages influence tumor biology and can exacerbate tumor cell
proliferation and infiltration.45 In certain types of epithelial and skin cancer, some helper T
cell cytokines have been implicated in cancer progression.46 The multi-functional nature
of cytokines illustrates the importance in understanding each component more fully in
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order to harness their ability to regulate differentiation, promote hematopoietic cell
maturation, and instigate immune cell activation in a host-defensive manner.
Cytokines: Conclusion
Perhaps the most intriguing and unanticipated characteristic of cytokines is their
polyfunctionality. Even cytokines that have very specific purposes, such as EPO and TPO,
influence cellular differentiation, proliferation, survival, and even activation and maturation.
The pleiotropic effects are not well understood. We know that a single type of cytokine
acting on the same type of receptor but in two different cells will activate parallel signaling
pathways that have distinct effects within each cell type. However, our current
understanding of cytokine biology is insufficient to explain this phenomenon. The
consequence of cytokine stimulation cannot be inferred from the receptor it activates but
its effect is influenced by differences in epigenetic state, presence of signaling molecules,
and transcription factor expression.47 The ability of cytokines to influence hematopoiesis
at all levels is further convoluted when the combinatorial effects of dual or triple cytokine
receptor stimulation are accounted for. In addition to simultaneous co-activation, cytokines
have a certain amount of inherent redundancy. For example, G-CSF, GM-CSF, M-CSF,
SCF, IL-3, and IL-6 all instigate proliferation and granulocyte colony formation.19 Not only
do cytokines have an impact on hematopoiesis, but their secretion and function is altered
in cancerous cells and they have proven efficacious in treating tumors, indicating that tight
regulation of these growth factors is necessary for the maintenance of normal
hematopoiesis.48 While experimental evidence has shown that external stimulation by
cytokines is necessary for maintaining HSCs and aiding in differentiation, a more
comprehensive understanding of hematopoiesis must also account for cell intrinsic
pathways.
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Transcriptional Regulation
One of the main forms of cell-autonomous hematopoietic regulation is through the
expression of transcription factors. Due to their pleiotropic nature, transcription factors,
like those described herein, have the ability to affect a variety of cellular processes
important for homeostasis and can influence the hematopoietic system at all stages of the
differentiation pathway. Though many transcription factors influence hematopoiesis,
certain central transcription factors have been shown to play critical roles, including
RUNX1, GATA1 and 2, and NOTCH1. These transcription factors each play a key role in
hematopoiesis and defects in their ability to regulate transcription in HSCs results in a
variety of problems from hematopoietic failure to disease development. Though alone
each of these transcription factors aids in hematopoietic regulation, the interplay and
integration of each signaling pathway provides layers of control that determine HSC selfrenewal and differentiation.
RUNX1
Runt-related transcription factor 1 (RUNX1), originally known as acute
myelogenous leukemia-1 (AML1) can be found throughout all stages of hematopoiesis
and in all lineages. RUNX1 forms a complex with core-binding factor beta (CBFβ) that
together recognize the consensus motif 5`-TGTGGT-3`. The gene for RUNX1 is located
on chromosome 21 and the full-length protein has two important domains: the runt
homology domain that recognizes the consensus motif and the transactivation domain. It
has been shown to have a role in hematopoietic differentiation and its dysregulation at the
genetic or the protein level, either through mutations or the formation of fusion genes,
alters myeloid differentiation leading to dysplasia and leukemia.49 In a non-malignant
setting, RUNX1 regulates many genes necessary for hematopoiesis, including many
cytokine, B cell, and T cell receptors.50 Runx1 deletion in the adult hematopoietic system
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causes expansion of the HSPC pool and induced pluripotent stem cells derived from cells
harboring RUNX1 mutations have impaired ability to develop into HSCs.51,52 While RUNX1
expression is necessary and sufficient for the maintenance of normal hematopoiesis,
elevated levels were shown to accelerate endothelial-to-hematopoietic transition that
resulted in myeloid malignancy development.53 RUNX1 and other related genes are
frequently mutated in AML, including many translocations involving chromosome 21 where
RUNX1 is located. RUNX1 can be directly dysregulated through loss of function point
mutations or fusion proteins like RUNX1-RUNX1T1 and TEL-RUNX1 or it can be indirectly
regulated such as through disruption of its own regulatory proteins like CBFβ.49
GATAs 1 and 2
GATAs 1 and 2 are X-linked genes characterized by their 5`-GATA-3` consensus
sequence recognized by a double zinc-finger domain. They come from a 6-member family
of transcription factors that all play unique roles in the development of a variety of tissues
with GATA1/2 being important for hematopoiesis. The founding member of this family,
GATA1, has been extensively studied for its relationship with hematopoiesis. Proper
GATA1 function is required for differentiation of erythroid cells, mast cells,
megakaryocytes, eosinophils, and basophils. While GATA1 does not have a direct effect
on HSPCs, loss of Gata1 blocked differentiation of megakaryocytes and erythroid cells
and increased their progenitor population.54 GATA2, on the other hand, has a more
prevalent role in HSPCs and even controls the differentiation of human embryonic stem
cells into HSCs.55,56
GATA1 and GATA2 can act independently to influence hematopoiesis though the
complexity and specificity of these transcription factors is revealed in studying the interplay
between them. At various stages of differentiation, analysis of chromosome occupancy
reveals that GATA1 and GATA2 localize to distinct sites and that their locations can
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reverse depending on the stage of differentiation.57 In fact, GATA1 and GATA2 occupancy
of the same locations within the chromatin but at distinct and separate times occurs at
many stages of differentiation. The occupancy pattern determines the ability of cofactors
to bind and determines the specific downstream effect.58 Despite extensive knowledge of
the essential function they play in hematopoiesis, dysregulation of GATA2 has only been
shown to directly correlate with malignancy within the past two decades.59 GATA2
upregulation indicates poor patient prognosis in AML, the L359V mutant promoted
accelerated phase CML, and mutations leading to GATA2 deficiency promote the
development of MDS and AML.60-62 GATA1 was also found to cooperate with AMLassociated mutations to promote molecular pathogenesis and has been proposed to be a
biomarker of patient prognosis.63
NOTCH1
While not a direct transcription factor, membrane bound NOTCH1 receptor is
cleaved upon ligand activation and the intracellular domain translocates to the nucleus
where it acts as a transcriptional repressor. There are four members of the NOTCH family,
though only NOTCH1 and NOTCH2 play a role in hematopoiesis. Many studies provide
evidence that NOTCH signaling is critical for normal hematopoiesis and that it has a role
in maintaining the self-renewal of HSCs. In CD34+ cells isolated from human cord blood,
induction of NOTCH signaling resulted in a large increase in the number of HSPCs and
enhanced their reconstitution ability.64 Indeed, NOTCH1 is essential for developmental
hematopoiesis, specifically in primitive endothelial hematopoietic progenitors where
imbalanced NOTCH1 signaling blocked the emergence of HSCs.65 NOTCH1 likely
influences HSC development by upregulating Foxc2 in hemogenic endothelial cells,
allowing them to progress to cells capable of undergoing definitive hematopoiesis.66
Constitutive activation, however, impairs the ability of hemogenic cells to undergo
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definitive hematopoiesis, providing further evidence that NOTCH1 activation must be
balanced in order to accurately regulate hematopoiesis.67 One method of NOTCH1
regulation was identified in a recent study where Notch1 regulation in HSCs was found to
occur at the post-transcriptional level through RNA-binding protein recognition of a
repressor sequence in the 3`UTR.68 Both NOTCH proteins have nonredundant roles in B
lymphocyte development, where NOTCH1 blocks T cell development and NOTCH2 is
required for marginal zone B cell development.69
NOTCH1 signaling plays an important role in lymphoid cell development in both B
and T cells. T cell commitment from the progenitor cells requires expression of specific
cytokines, such has IL-7, but also necessitates the activation of specific signaling
pathways, one of which is NOTCH signaling. Expression of the NOTCH ligand in thymic
tissues enables the thymus to acquire the necessary environment for T cell
development.70 Within the T cell themselves, NOTCH1 signaling is required for T cell
potential and silencing of this pathway acts as an exclusionary process to force B lineage
commitment.71 Mutations that over-activate NOTCH1 signaling in the T cells result in the
accumulation of tumorigenic T cells and is responsible for about 60% of T-ALL cases.72
Initially, NOTCH signaling deactivation allows for B cell development but the reactivation
of this pathway is necessary for complete B cell maturation into antibody-secreting cells.73
While not as common as in T cell leukemia, mutations in NOTCH1 have been seen in de
novo (~10% of cases) and recurrent CLL (up to 20%).74 CLL mutations occur within a
regulatory domain necessary for NOTCH degradation so mutations within this domain lead
to an accumulations of active NOTCH.75
Together, RUNX1, GATA1/2, and NOTCH1/2 constitute some of the primary
hematopoietic transcription factors. Each one plays an important and non-redundant role
in HSC regulation and determination of differentiation. Their ability to cooperate with each
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other and with other transcription factors not described herein, creates an intricate and
complex network of transcriptional regulation. When errors occur within this network, they
often lead to malignant transformation. As was described with RUNX1, aberrant signaling
due to loss of function or altered activity through fusion protein development leads to
leukemogenesis. Proper hematopoiesis depends upon the accurate functionality of this
network and, for the most part, it is well-maintained. Together, cytokine signaling and
transcription factor expression represent two of the major regulators of hematopoiesis but
they do not account for regulation at the post-transcriptional level.
Ubiquitin Proteasome System Regulation
One post-translational regulatory system that has emerged as an important
regulator of normal and malignant hematopoiesis is the ubiquitin proteasome system
(UPS). The UPS coordinates the degradation of proteins globally and compartmentally
within a cell and is a key regulatory mechanism for a variety of cellular processes including
cell cycle progression, proliferation, development, and differentiation.76 Dysregulation of
the UPS has been shown to have a high correlation with aberrant differentiation as well
as cancer initiation and progression.77-79 This system functions through an enzymatic
cascade in which the E1 ubiquitin activating enzyme activates a small protein marker
called ubiquitin, which is then conjugated to an E2 ubiquitin-conjugating enzyme and
subsequently passed to a substrate protein through interaction with an E3 ubiquitin ligase.
Proteins that receive a poly-ubiquitin chain are then recruited to the proteasome for
proteolysis and the individual components (amino acids, ubiquitin molecules, and other
post-translational modifications) are recycled for subsequent use in the cell. The key
components of this system are the E3 ubiquitin ligases due to their critical role of
determining substrate specificity.
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Each E3 ubiquitin ligase mediates the transfer of ubiquitin from an E2 to a lysine
residue within a specific set of substrate proteins that receive a K48-linked poly-ubiquitin
chain. Poly-ubiquitination with a K48 linkage is specific to proteins tagged for degradation.
Since the E3 ligases determine substrate ubiquitin modification, there are over 600 known
E3 ligases that each recognize a specific set of substrates while the other UPS enzymes
combined, E1 and E2, total less than 50.80 E3 ubiquitin ligases can be classified as
homologous to the E6-AP carboxyl terminus (HECT) domain, really interesting new gene
(RING)-finger, or RING-between-RING (RBR) based on their domains and mode of
transferring ubiquitin to the substrate. There are about 30 proteins belonging to the HECT
E3 ligase class that all contain a conserved c-terminal HECT domain.81 These proteins
are unique in that they bind to the E2 and transfer the activated ubiquitin to a catalytic
cysteine within the HECT domain which then directly transfers the ubiquitin to the
substrate protein. RING E3 ligases comprise the largest subset of ubiquitin ligases and
contain a canonical RING finger domain, made up of multiple cysteine and histidine
residues interspersed with other amino acids, that interacts with two zinc ions.82 Unlike
HECT E3 ligases, RING finger proteins do not directly conjugate the activated ubiquitin
but rather act as a scaffolding protein (or protein complex) to bring the E2 in proximity with
the substrate.81 The last class, the RBR E3 ligases, act as a combination of the other two.
The first RING domain facilitates discharge of the ubiquitin from the E2 onto the second
RING domain that forms a thioester intermediate with a catalytic cysteine similar to the
function of the HECT domain.83 The largest family of E3 ligases is the SKP1-CUL1-F-box
(SCF) family of RING E3 ligases.84
SCF ligases are named for the various components that compose the core of the
complex.85-88 S-phase kinase-associated protein 1 (SKP1) and Cullin 1 (CUL1) act as
scaffolding proteins that bring the ubiquitin binding RING finger protein RBX1 in proximity
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with the substrate recognition F-box protein component (Figure 1A).77,89 To date, 69
distinct F-box proteins have been identified, each of which contains an F-box domain and
a protein recognition domain.90,91 The proteins in this family interact with SKP1 via the Fbox domain and bind to substrate proteins through a protein-binding domain. This family
of proteins is subdivided into three categories based on their protein-recognition
sequences: FBXL proteins contain leucine rich repeats, FBXW proteins contain WD
repeats, and FBXO proteins contain a variety of protein recognition domains or have an
unidentified protein-binding site (Figure 1B).92,93 Most F-Box proteins recognize substrates
that are phosphorylated at a specific serine- or threonine-containing amino acid sequence
known as a phosphodegron. The phosphodegron sequence is specific to each E3 ligase
and allows for substrate recognition, binding, and subsequent poly-ubiquitination.
F-box proteins are responsible for recognizing about 20% of the proteins degraded
by the UPS and have been found to ubiquitinate substrates important for cell survival, cell
cycle regulators, transcription factors, and cell-surface receptors.94,95 They are responsible
for regulating the expression and activity of a variety of tumor suppressors and oncogenes
and target proteins involved in the hallmarks of cancer pathways, making them interesting
proteins for study in normal and malignant hematopoiesis.96 The following sections will
investigate the various F-box proteins that have been shown to regulate normal and
malignant hematopoiesis.
F-box regulation of HSPCs and malignant transformation
The balance between HSPC quiescence, self-renewal, and differentiation is
carefully controlled. A shift toward quiescence leads to the inability of the hematopoietic
system to replenish the mature cells, whereas a shift toward differentiation results in stem
cell exhaustion or development of leukemia. Recent work has shown that F-box proteins
play an integral role in maintaining that balance. Alterations in the activity of certain key
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E3 ligases have been correlated with loss of quiescence, aberrant differentiation, and
malignant transformation. Many F-box proteins play a role in cell cycle regulation, while
others have been shown to assist in the maintenance of quiescence and still others have
alternative functions that affect the hematopoietic system.
Cell cycle regulation
The cell cycle consists of five different phases: growth, synthesis, growth, mitosis,
and growth arrest/quiescence (G1, S, G2, M, and G0). Cells that are actively dividing spend
the majority of their time in the G1 state in which they grow and prepare for DNA and
organelle synthesis. The rate at which cells pass through G1 varies from one cell to
another. From this point, they can enter one of two pathways: the more common choice
among cells is to begin the process of synthesis in which DNA and organelles are
replicated to accommodate two daughter cells. After S phase, the cells enter a second
growth stage, G2, preparatory for mitosis in which cellular fission occurs to produce two
daughter cells. Mitosis can occur in a symmetric or asymmetric fashion to give rise to two
identical or two distinct daughter cells. Progression through the cell cycle is controlled by
the coordinated, serial expression of cyclins (CCN) and cyclin dependent kinases (CDKs).
The primary cyclins and CDKs responsible for proliferation include CCND-CDK4/6
predominantly expressed in G1, CCNE-CDK2 that regulates G1-S transition, CCNA-CDK2
that controls the transition from S into G2, CCNA-CDK1 that acts during G2 and in the
transition into M, and CCNB-CDK1 that is important during mitosis.97
The second pathway that cells can take from G1 is to enter into G0: a reversible
quiescent state in which they remain dormant for periods of time. Like other stem cells
within the body, HSCs exist in a primarily quiescent state but retain the ability to reenter
the cell cycle to generate mature cells. Though the exact mechanism by which HSCs enter
and exit quiescence has yet to be fully elucidated, reports indicate that cells such as
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osteoblasts within the stem cell niche secrete factors that preserve stemness within that
compartment.98 Both cell cycle progression and quiescence are important cellular
processes that are often dysregulated in malignancies. Many F-box proteins regulate the
expression of proteins involved in the cell cycle and eight have been shown to have direct
correlations with hematopoiesis (Figure 2).
SKP2 (or FBXL1)
One of the earliest identified F-box proteins, src-associated kinase 2 (SKP2), was
discovered and named prior to the realization that it belonged to the SCF family of E3
ligases. SKP2 has long been shown to regulate cell cycle progression by associating with
the CCNA-CDK2 complex and by ubiquitinating CDK inhibitors that prevent the G1-S
transition including p21.99,100 SKP2 expression is often increased in cancer patients
resulting in an increase in proliferation through degradation of those key cell cycle
inhibitors. SKP2 also plays a role in regulation of HSPCs and is increased in response to
myeloablative therapies, preventing inhibition of cell cycle progression and allowing the
HSPCs to repopulate the mature cell lineages.101 Indeed, inhibition of Skp2 following
myeloablative therapy impaired the ability of HSPCs to engraft and repopulate in
transplant mice.101
Contrary to the reports that SKP2 is necessary for BM repopulation, another group
found that in freshly isolated HSCs, knockout of SKP2 enhanced long-term reconstitution
by increasing cell cycle progression and augmenting the HSC pool size.102 This disparity
likely stems from a difference in substrate recognition of SKP2 within HSCs, giving it a
method of regulation distinct from that of non-malignant mature cells and leukemic cells.
SKP2 activity and its regulation of cell cycle progression has implications in treatment
regimens, particularly with regard to leukemic stem cells (LSCs), and its inhibition may
prove efficacious in combination therapies.102,103 Though SKP2 primarily plays a role in
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cell cycle regulation, it was additionally found that the loss of SKP2 prevents HSC homing
to the BM and spleen by downregulating β-catenin at a transcriptional level.104 The
example of SKP2 illustrates the multifaceted role that many F-box E3 ligases play in
hematopoiesis: its primary known function regulates cell cycle progression but its
additional roles through alternative substrates allow it to coordinate a variety of processes
and signaling pathways that promote cell survival.
β-TrCP1/2 (or FBXW1/FBXW11)
β-transducin repeat-containing proteins one and two (β-TrCP1 and 2), collectively
known as β-TrCP, play a major role in cell cycle progression by targeting multiple cell cycle
regulators for degradation at the proteasome. β-TrCP is uniquely capable of promoting
and inhibiting cell cycle progression either by degrading claspin and WEE1 to activate
cycling or CDC25A and EMI1 to arrest progression.77 β-catenin, one of the primary β-TrCP
substrates, and the Wnt signaling pathway are essential for fetal HSPC development and
provide protection from oxidative stress.105 A regulatory protein for the Wnt/β-catenin
pathway, glycogen synthase kinase-3, participates in LSC pathophysiology.106
Dysregulation and expression alterations of both β-TrCPs have been found in leukemia
patients. For example, the overexpression of β-TrCP2 in a lymphocytic leukemia cell line
led to increased proliferation in vitro and enhanced tumor development in vivo.107 An Fbox deleted mutant of β-TrCP1 acted as a dominant-negative in myeloma cells, blocking
engraftment and cell survival in immunocompetent and immunodeficient mice.108 Further
analysis of hematopoietic cells expressing the β-TrCP ΔF-box mutant showed they were
unable to home to the BM and were consequently more susceptible to apoptosis.
Furthermore, treatment with a β-TrCP inhibitor reduced tumor burden in mice, indicating
a potential for use of β-TrCP inhibitors in combination therapies to treat hematologic
diseases, especially those with increased β-TrCP expression.108 Like β-TrCP, some F-box
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proteins have been found to regulate the cell cycle at various phases by targeting different
substrates.
FBXL12
Functional studies of FBXL12 began when it was identified as the E3 ligase
responsible for ubiquitinating two proteins that have distinct roles within the cell cycle:
Ku80 and calmodulin kinase I (CAMKI). Ku80 assists in the activation of the
nonhomologous end joining double-strand break repair pathway and FBXL12-mediated
ubiquitination initiates its removal from DNA prior to and following DNA damage repair
(DDR).109 This is an important step during S-phase because without functional DDR
mechanisms, cell cycle progression can either stall or continue despite the accumulation
of mutations, some of which might instigate disease formation. FBXL12 also regulates the
cell cycle at an earlier stage through regulation of CAMKI. This protein plays a critical role
in G1 progression by regulating CCND-CDK4 assembly and its ubiquitination by FBXL12
causes cell cycle arrest during G1 transition.110 In hematopoiesis, FBXL12 has the
additional role of regulating T cell maturation and proliferation by degrading aldehyde
dehydrogenase 3 (ALDH3) and cyclin-dependent kinase inhibitor 1B (CDKN1B).
Both FBXL12 mRNA and protein are highly expressed in the thymus, the primary
organ for T cell development. Knockout of FBXL12 had no effect on the number of
immature CD4 and CD8 double positive T cells but reduced the number of CD4 single
positive and CD8 single positive T cells.111 FBXL12 was found to be highly expressed in
the double positive T cells and ALDH3 levels were shown to be inversely related within
that population. This suggests that FBXL12-mediated degradation of ALDH3 caused a
block in T cell differentiation at the double positive to single positive transition. More recent
studies have shown that FBXL12 also mediates T cell proliferation to induce maturation
from the immature double negative to the double positive state. It does so by working in
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concert with SKP2 to destabilize CDKN1B, which in turn promotes the proliferative burst
that occurs as T cells mature.112 As has been shown with FBXL12 and other proteins
previously discussed, members of the F-box family often have a variety of functions within
the cell.
FBXW7
The most well-characterized F-box E3 ligase in the hematopoietic system is
FBXW7. This protein plays a critical role in maintaining HSCs and preventing
tumorigenesis by regulating HSC quiescence. FBXW7 is most well-known for the
ubiquitination and subsequent degradation of c-Myc, NOTCH, CCNE, and MCL1.113-116
Loss of Fbxw7 in murine BM HSCs increased their proliferation and resulted in premature
exhaustion of normal HSCs.117 FBXW7 regulation of HSCs occurs primarily through c-Myc
and NOTCH1. HSC quiescence is maintained in the absence of c-Myc, a protein that
causes the release of stem cells from the niche resulting in their entry into the cell cycle.118
Cell cycle progression and HSC differentiation is then accelerated upon accumulation of
NOTCH.119 Co-expression of c-MYC and NOTCH in HSCs can be useful in repopulating
the hematopoietic system under conditions of disease or injury but without FBXW7 activity,
persistent expression leads to eventual stem cell exhaustion and pancytopenia.
FBXW7 regulates the cell cycle by targeting CCNE, the primary cyclin responsible
for coordinating the G1 – S transition. Two knockin mutations, T74A and T393A, were
generated in murine CCNE that resulted in the inability of FBXW7 to interact with and
ubiquitinate this cyclin. Interestingly, increased CCNE expression did not impair HSC selfrenewal but rather caused a defect in multilineage reconstitution.120 However, further
interrogation of the system by loss of p53 exacerbated the reconstitution defects, impaired
HSC self-renewal, and led to the emergence of chromosome instability.120 Together, these
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studies illustrate the critical role of FBXW7 in regulating normal HSC stability and
differentiation.
Multiple cancer-related FBXW7 mutations have been shown to occur in a variety
of mouse and human carcinomas including T-ALL and CML.121-123 The majority of these
mutations affect three arginine residues within the WD40 protein-binding domain that
inhibit the binding to phosphorylated substrates.124 Both Agrawal et al. and Le Gallo et al.
identified hemizygous cancer-promoting mutations, making FBXW7 unique in that most
tumor suppressors require deleterious mutations in both alleles prior to oncogenic
transformation. This is likely due to the fact that FBXW7 dimerizes prior to carrying out its
ligase activity. Thus, a heterozygous mutation could affect a larger percentage of the total
FBXW7 dimers than the 50% of proteins it would affect if it did not dimerize. Several loss
of function FBXW7 mutations have been described in T-ALL that likely contribute to
pathogenesis through loss of NOTCH degradation. This is supported by the finding that,
in T-ALL, FBXW7 mutations and NOTCH mutations in the phosphodegron PEST domain
are mutually exclusive.125 Interestingly, not only is FBXW7 a tumor suppressor whose loss
or impairment paves the way for tumorigenesis, but reports have shown that certain
mutations within FBXW7 result in the formation of oncogenic mutants as was shown in
increased tumor formation in T-ALL xenografts with the FBXW7D527G or FBXW7D510E
mutations.126
The tumor suppressive nature of FBXW7 and its ability to regulate HSC
quiescence make it an interesting protein for the study of LSCs, a rare subpopulation that
remains primarily quiescent but is necessary for leukemia cell propagation. A major
impediment to leukemia eradication lies in the inability of current therapies to target LSCs,
as the conventional chemotherapies require cellular proliferation for their toxicity to take
effect. In both T-ALL and CML, FBXW7 regulation of LSC quiescence has been studied.
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In T-ALL, loss of FBXW7-mediated ubiquitination of c-Myc was found to increase the
number of LSCs.127 In CML, FBXW7 had the opposite effect by stabilizing LSCs through
reduction of c-Myc levels. Ablation of FBXW7 initiated cycling of LSCs, making them
vulnerable to tyrosine kinase inhibitor treatment.128,129 Like FBXW7, some F-box proteins
have many identified substrates and well characterized mechanisms of action but for
others the precise substrates remain unknown.
FBXL5
FBXL5 affects murine HSPC function by regulating iron homeostasis which, in turn,
affects HSPC ability to engraft and reconstitute mature blood cells.130 Muto et al. also
found that Fbxl5-deficient HSCs are more susceptible to oxidative stress and are prone to
loss of quiescence and stem cell exhaustion. Patients with myelodysplastic syndrome
(MDS) were found to have reduced FBXL5 expression, perhaps contributing to
hematopoietic failure as is characteristic of MDS.130 While some members of the F-box
family, like SKP2 and FBXW7, have been extensively studied and their roles in cell cycle
regulation well defined, others like FBXL5 are only beginning to emerge as cell cycle
regulators.
FBXL2
As with the previously mentioned F-box proteins, FBXL2 plays a role in cell cycle
regulation by targeting one of the cyclins, CCND2, for degradation. Unlike most F-box
proteins that recognize phosphodegrons, FBXL2 recognizes a calmodulin-binding motif
and must outcompete calmodulin in order to interact with its substrates.131 Patients with
acute leukemias have often been found to have increased levels of CCND2 and
decreased FBXL2, which aligns with the finding that the reintroduction of FBXL2 causes
G0 arrest and apoptosis in leukemic cell lines.131 In the case of FBXL2, further investigation
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focusing on its upstream regulation, as opposed to its downstream targets, may aid in the
development of targeted therapies for treating acute leukemias. The previously mentioned
F-box family proteins, including FBXL2, have been shown to regulate cell cycle
progression and other pathways important for maintaining hematopoiesis. However, not
all F-boxes have been shown to have direct links to hematopoiesis or hematologic
malignancies but we can infer their role through analysis of their substrates.
FBXO4
One of the hallmarks of cancer is uncontrolled proliferation, which often coincides
with mutations that lead to the overexpression or stabilization of cell cycle promoters like
CCND1.132 As previously described, progression through the cell cycle is controlled by the
sequential expression of cyclins and CDKs which, in turn, are controlled by coordinated
expression of E3 ubiquitin ligases that tag them for degradation at the proteasome.
Aberrant cyclin and CDK expression results in an inappropriate halt in or progression
through the cell cycle that often leads to disease development. In nearly 100% of mantle
cell lymphoma (MCL) patients, CCND1 is constitutively activated causing B cells to
progress through the cell cycle with unchecked proliferation.133 Under normal conditions,
CCND1 is ubiquitinated for degradation by the FBXO4-αβ crystallin complex after
phosphorylation of T286 by glycogen synthase kinase 3β.134 FBXO4 has yet to be directly
linked to MCL but inactivating mutations have been identified in various cancers including
esophageal carcinoma.135 As with FBXO4, most research focuses on the downstream
targets of E3 ligases for study but an understanding of the signaling cascades that regulate
ubiquitin ligases provides a deeper understanding of the intricate network surrounding E3
ligase function.
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FBXO6
One F-box protein whose upstream regulation has been studied is FBXO6.
Regulation of FBXO6 in t(8;21) leukemic cells occurs through mitogen-activated protein
kinase (MAPK) signaling, a cascade frequently associated with the t(8;21) translocation.
Depletion of the MAPK signal cascade component ERK2 led to increased expression of
FBXO6.136 The group conducting this study concluded that ERK2 expression in t(8;21)
AML promotes proliferation by increasing cell cycle progression through regulation of
genes including FBXO6. Downstream from FBXO6 is the protein checkpoint kinase 1
(CHK1), yet another cell cycle regulator. CHK1 is responsible for delaying cell cycle
progression while stabilizing the replication fork until DNA repair occurs and synthesis
resumes. Almost counterintuitively, CHK1 expression positively correlates with cancer
stage and recurrence since its activity can aid in tumor cell survival by preventing the overaccumulation of mutations.137 As with other cell cycle regulatory proteins, CHK1 is
degraded by the proteasome and is targeted for ubiquitination by the SCF-family protein
FBXO6.138
FBXO6 reportedly plays a direct role in myeloid leukemia, likely through regulation
of CHK1, and has also been shown to regulate the innate immune response, likely through
a different mechanism. Type I interferons (IFN-I) activate the innate immune response but
their prolonged activation can lead to autoimmune inflammatory diseases; thus, IFN
activation is carefully controlled. FBXO6 was identified as an E3 ubiquitin ligase for IRF3,
an IFN-I regulatory protein, and its activity negatively regulates IFN-I signaling, thus
preventing inappropriate or excessive inflammation.139 Like FBXO6, some F-box proteins
are better known or were initially identified for their role in non-hematologic systems.
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FBXO7
Largely studied for its role in Parkinson’s disease and mitophagy, FBXO7 also has
a cell cycle regulatory function by mediating the CCND-CDK6 interaction and stabilizing
p27.140 Interestingly, it is its non-canonical, non-ubiquitinating function that allows FBXO7
to regulate hematopoiesis. Instead of destabilizing the CCND/CDK6 complex through
ubiquitin-mediated degradation, FBXO7 assists in the assembly of this cell cycle
regulatory complex. In the hematopoietic system, increased Fbxo7 inhibited the colony
forming ability of HSPCs in a p53-dependent manner.141 Additionally, loss of Fbxo7 in the
hematopoietic system enhanced proliferation in a variety of cell lines by accelerating the
G1 phase of the cell cycle resulting in smaller, more abundant cells, a characteristic that
has previously been linked to cancer development.142
FBXO7 was also found to have an inverse correlation with CD43, a marker for
immature B cells, indicating that it integrates the regulation of cell cycle progression and
differentiation, two mechanisms that have not previously been linked through activity of a
single protein.142 In mice, its expression was also found to be linked to the prevention of
anemia by stabilizing p27 and causing cell cycle arrest in terminally differentiating
erythroblasts, allowing them to become mature RBCs.143 Stabilization of p27 represents a
non-canonical and contradictory function to the normal E3 ligase degradation for which
this protein is responsible. Furthermore, aberrant expression of this protein in HSPCs
cooperated with p53 deletion to promote tumor formation.141 This protein’s ability to act in
a non-ubiquitination function is not unique within the F-box family nor even within the
subset that regulate hematopoiesis. Other F-box proteins have also been shown to have
roles that do not necessitate the E3 ligase ubiquitination function.
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Non-canonical functions
The primary function of F-box proteins resides in their ability to assist in the
ubiquitination and consequent degradation of substrate proteins. However, some
members of this family play unpredicted roles that may or may not utilize the ubiquitination
capability to effect a change in the cell.
KDM2B (or FBXL10)
As part of the polycomb repressive complex (PRC), the main function of lysine
demethylase 2A and 2B (KDM2A and KDM2B) is in the di-demethylation of histone H3
lysine K26. The PRC alters the epigenetic landscape of CDK inhibitor promoter regions,
decreasing their expression.144 KDM2B, specifically, has been shown to be important for
developmental and definitive hematopoiesis by regulating integral pathways such as
NOTCH or Wnt and loss of this protein impairs normal HSPC function and alters
proliferation.145 Many leukemia patient samples were found to have high KDM2B
expression

that

correlated

with

increased

HSPC

proliferation

and

malignant

transformation.146
KDM2B has also been shown to induce transcriptional repression that results in
increased proliferation in MDS.147 Perhaps of most interest, it is highly expressed in HSCs
and maintains their self-renewal capability.144 Uncontrolled overexpression in a mouse
model, however, led to the development of myeloid or B cell leukemias with 100%
penetrance, indicating that KDM2B expression must be carefully controlled in order to
prevent malignant transformation.148 Additionally, its knockdown has been shown to
decrease the self-renewal capacity of LSCs, a notoriously difficult population to target. 146
As a component of the PRC complex, KDM2B primarily functions as a histone
demethylase rather than an E3 ligase, though its ubiquitination function may be necessary
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for complete PRC activity. Previous work has shown that FBXL10 monoubiquitinates
histone H2A, a necessary modification for recruitment of the PRC complex to the DNA.
H2A monoubiquitination may also function as an epigenetic marker for recruitment of other
transcription factors.149
KDM2A (or FBXL11)
Methylation patterns vary greatly, with some signatures stably maintained through
mitosis and others that change throughout the lifetime of the organism. A study of serial
peripheral blood (PB) collections from children beginning at three months of age and
continuing through five years demonstrated that genes responsible for chromatin
remodeling, including KDM2A and KDM2B, undergo dynamic epigenetic alterations in
leukocytes throughout early childhood.150 Not only is methylation important for gene
expression in early childhood development, but it acts as a regulatory mechanism of
normal and malignant hematopoiesis.
Two histone methyltransferases necessary for hematopoietic development include
ASH1L (absent, small, or homeotic discs 1 like) and MLL (mixed lineage leukemia) that
methylate H3 at lysines K36 and K4, respectively.151,152 Chromosomal translocations
involving the MLL gene often result in leukemogenesis. KDM2A, like its paralogue
KDM2B, is a histone di-demethylase preferential to H3K36me2 and is the counterpart to
ASH1L. Over-expression of KDM2A, specifically, was shown to oppose ASH1L activity by
demethylating chromatin at MLL target genes that subsequently reduced WT MLL
chromatin occupancy.153 Though it had no effect on MLL-fusion protein chromatin
occupancy, KDM2A counteracted MLL-driven transcription and suppressed leukemic
transformation. KDM2A has a separate and contrary role in STAT5-induced B-ALL. In this
context, Stat5 and Kdm2a activation cooperate to drive leukemogenesis and levels of
KDM2A inversely correlate with patient survival.154 The previously reported F-box proteins
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have all been shown to have either a direct or indirect role in cell cycle progression within
the hematopoietic system but the remaining F-boxes discussed herein regulate normal
and/or malignant hematopoiesis through other mechanisms.
Regulation of other pathways
As has been described with some of the previously mentioned members of this
family, F-box protein function is not limited to cell cycle regulation. Many F-box proteins
act in a cell cycle regulatory fashion but have additional functions that influence other
mechanisms or specific hematopoietic lineages. Other F-box proteins have not been
shown to impact cell cycle progression but have been shown to play other roles in
hematopoiesis (Figure 3).
FBXL13
FBXL13 was investigated as a potential tumor suppressor gene in AML and MDS.
One leukemia-initiating mutation particularly prevalent in t-AML is monosomy 7 or
del(7q).155 Curtiss et al. identified a region of 7q22 commonly deleted in patients that
contained 14 known genes, including FBXL13. After sequencing several leukemia
samples for functional mutations in FBXL13 and analyzing the same samples for
epigenetic expression changes affecting mRNA production, the authors concluded that
there was insufficient evidence to classify FBXL13 as a novel tumor suppressor.156 The
inconclusive evidence does not preclude FBXL13 from hematopoietic regulation or tumor
suppression but illustrates the need for deeper investigation into the mechanistic changes
that occur when FBXL13 E3 ligase activity is lost in both healthy and disease states.
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FBXO9
Relatively little is known about the E3 ligase function of FBXO9 particularly as it
relates to the hematopoietic system. Previous studies have shown a link to adipocyte
differentiation wherein FBXO9 was highly expressed in obese mice and functions by
reducing levels of CCAAT/enhancer binding protein β.157 While FBXO9 does not appear
to directly affect this protein, it was later found to facilitate the ubiquitination and
degradation of peroxisome proliferator-activated receptor gamma.158 Other known
substrates include telomere maintenance 2 (TEL2) and TEL2 interacting protein 1 (TTI1),
in the context of multiple myeloma (MM).159 Its overexpression in this disease was linked
to enhanced proliferation and survival of malignant cells. Knowing that FBXO9 plays a role
in adipocyte differentiation and MM, it is conceivable that it could also regulate
hematopoietic differentiation and malignant transformation. Herein, we report that Fbxo9
is highly expressed in murine HSCs but that its knockout resulted in only marginal changes
in HSPCs within the BM. Though knockout of Fbxo9 does not directly cause malignant
transformation, when combined with expression of an AML fusion protein, it led to
increased AML blasts within the BM, a more aggressive disease, and a shorter time of
survival.160
FBXO11
Though hematopoietic differentiation begins in the BM, many stages of maturation
occur in the secondary hematopoietic organs. B cells fully mature in the spleen, of which
the germinal centers are critical areas of differentiation and maturation. Expression of the
transcriptional repressor B cell lymphoma 6 (BCL6) is necessary for proper germinal
center development and its inactivation is crucial for post-germinal center differentiation.161
Mutations that cause aberrant regulation of germinal centers and dysregulation of BCL6
lead to the formation of hematologic malignancies. BCL6 expression is switched off
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through multiple signaling pathways and by the proteasome through FBXO11-mediated
ubiquitination.162 Similar to the phenotype observed with increased BCL6, inactivation of
FBXO11 in germinal centers led to their enlargement, loss of homeostasis, and
lymphomagenesis.163 Analysis of FBXO11 highlights the important role that many of these
F-box proteins play: many have been shown to be important for maintaining normal
hematopoietic cell development and changes in their expression, either up or down, can
lead to the initiation or progression of malignancies.
F-box conclusion
As illustrated above, the hematopoietic system is carefully regulated by the UPS
through many F-box family proteins. While some have been shown to have a large impact
on many facets of normal and malignant hematopoiesis, such as FBXW7, others have
weaker correlations, like FBXL13. Herein, we comment on 15 of the 69 F-box proteins
with known functions associated with hematopoiesis but that does not preclude the other
54 from also playing a regulatory role in blood cell development. Indeed, many F-box
proteins not previously discussed play important roles in systems critical to hematopoiesis
and disease prevention/progression. This is highlighted by the example of FBXO4, a
protein not directly linked to the hematopoietic system but one whose substrate
ubiquitination is critical for cell cycle regulation by CCND – a protein known to be integral
to MCL development. The majority of the proteins discussed herein regulate cell cycle
progression, but other F-box proteins are involved in processes such as development and
apoptosis, two additional processes critical for homeostasis. Though their function in
hematopoiesis has not yet been elucidated, it is likely that many of these proteins regulate
pathways necessary for hematopoiesis. The diversity of functions of F-box proteins
illustrates the importance of elucidating the role of each family member and determining
their functions in hematopoiesis.
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Figure 1

A

B

Figure 1 F-box components determine substrate specificity within the SCF family
of E3 ubiquitin ligases. A Schematic of the SCF complex containing SKP1, CUL1, an Fbox substrate recognition component, and the ubiquitin-binding RBX1 and UBC
components. B Subclasses of F-box proteins that each contain a F-Box domain, and a
substrate-recognition domain. FBXL members contain leucine rich repeats, FBXW
members contain WD repeats, and FBXO members contain another substrate recognition
motif or only have an identified F-Box domain.
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Figure 2

Figure 2 F-box proteins regulate the cell cycle in the hematopoietic system. Model
of the cell cycle including prominent cyclin-CDK complexes as regulated by F-box proteins
either directly or via other cell cycle regulators. Activation in green, inhibition in red.
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Figure 3
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Figure 3 F-box proteins regulate hematopoiesis. Schematic of hematopoiesis including
F-box proteins known to regulate specific branches.
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Table 1 Common leukemia subtypes
CLL

ALL

CML

AML

Cell type

Lymphoid

Lymphoid

Myeloid

Myeloid

Presentation

Chronic

Acute

Chronic

Acute

Median age

72

12

64

68

91%, 68.6%

67%

27%

5 year survival 83%
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CHAPTER 2:
FBXO9 IN NORMAL HEMATOPOIESIS
Portions of this chapter have been published as: Hynes-Smith, R. W. et al. Loss of
FBXO9 Enhances Proteasome Activity and Promotes Aggressiveness in Acute Myeloid
Leukemia. Cancers (Basel) 11, doi:10.3390/cancers11111717 (2019).
Hematopoietic development and differentiation
The word hematopoiesis is derived from the Greek words for “blood” and “to make”
and the process is responsible for generating blood cells throughout the life of an
organism. Hematopoiesis occurs in two waves during development.164 In the first wave
known as primitive hematopoiesis, blood cells begin to emerge at early stages of
embryogenesis, typically within days of fertilization, and develop in the yolk sac and
intraembryonic hemogenic sites.165,166 These early loci of blood cell development are
unable to support terminal differentiation and cannot sustain cell generation. The second
wave, definitive hematopoiesis, first appears in the aorta-gonad-mesonephros where
HSCs first emerge and then migrate to the fetal liver. Shortly after seeding in the liver, the
HSC population rapidly proliferates to increase the number of stem cells. This accelerated
growth is sustained for a few days, after which HSCs begin the process of self-renewal
and differentiation that gives rise to mature hematopoietic cells.167 Once differentiation
supersedes expansion, the process changes to accommodate requirements of the fetus,
beginning with a focus on erythropoiesis and later differentiating more evenly into WBCs.
Just prior to birth, the HSCs migrate from the liver to the BM where they remain for the
duration of the organism’s life and generate all blood cell lineages.
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Adult hematopoiesis
Following birth, HSCs within the BM have the immense task of providing adequate
blood and immune cells to sustain life and prevent disease. The classical hematopoiesis
model describes hematopoietic cell development as a hierarchical process beginning with
the HSCs, including both quiescent LT-HSCs and self-renewing ST-HSCs. The ST-HSCs
further differentiate to become a multipotent progenitor (MPP) incapable of self-renewal
and committed to the differentiation pathway. From there, MPP cells can enter one of two
pathways: the first of which is a common lymphoid progenitor (CLP) from which T cells, B
cells, and natural killer (NK) cells develop. The second pathway is the common myeloid
progenitor (CMP) that further differentiates into either a granulocyte-monocyte progenitor
(GMP) and subsequent granulocytes and macrophages or into a megakaryocyte-erythroid
progenitor (MEP) that gives rise to erythrocytes and platelets (Figure 4).
For many years, this hierarchical model remained unquestioned but recent
evidence supports the claim that this system is not as rigid as initially described and that
more flexibility exists, particularly within the progenitor cell populations.168,169 A majority of
the differentiation process occurs in the BM where the HSCs reside with maturation often
completing in secondary hematopoietic organs such as the spleen or thymus. The
following sections will address the three main classes of hematopoietic cells and their
development: HSPCs, lymphocytes, and myeloid cells.
Hematopoietic stem and progenitor cells
The HSCs are vital to survival and are responsible for generating all mature blood
cells throughout the life of an organism, on average > 1011 per day.170 The existence of
these critical cells was first proposed in the 1960s and only later proven to be correct. 171
Initially, experts in the field debated whether hematopoietic cells originated from
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multipotent stem cells or from a set of oligopotent progenitor cells. The first observation of
these cells occurred via a series of experiments testing radiation sensitivity in mice that
later were further characterized through colony-forming assays.172,173 These and other
findings proved that the initial hematopoietic cells are multipotent stem cells and capable
of giving rise to multiple specialized cell types within the blood. The proposed system in
the 1960s was based on a stochastic model. In this model, a homogenous pool of stem
cells resided within the BM and randomly chose to either self-renew or differentiate. Over
the next two decades, this theory evolved and in the late 1970s, the “generation-age”
hypothesis proposed the existence of three distinct subsets of HSPCs with specific and
unique functions for self-renewal and differentation.174 This model was later proven
correct.
There are three types of undifferentiated hematopoietic cells lacking lineage
markers (Lin-) all collectively identified by the cell surface markers Lin-Sca-1+cKit+ (LSK).
LSKs comprise a heterogenous set of cells with distinct surface markers and differentiation
capabilities. Ultimately, these cells were classified using four cell surface markers known
as SLAM family markers, consisting of CD150, CD48, CD229, and CD244.175 Oguro et al.
identified seven distinct populations, though they can be simplified into three subgroups:
LT-HSCs that are CD150+CD48-, ST-HSCs that are CD150-CD48-, and MPPs that are
CD48+. The more specific subdivisions are summarized in Table 2.
Both LT- and ST-HSCs are capable of self-renewal and differentiation and, on
average, cycle once every 40 weeks in humans and once every 2.5 weeks in mice. 176,177
LT-HSCs remain primarily quiescent while ST-HSCs are more actively dividing, typically
in an asymmetric fashion to produce one daughter cell that remains an ST-HSC and one
daughter cell that becomes an MPP.178 Maintenance of the HSC pool is of vital importance
as these cells are capable of radioprotection and can be used for transplantation to treat
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disease.179 Though these cells are capable of long-term reconstitution, they are limited to
a finite number of cell divisions, as has been shown using serial transplantation
assays.180,181 Originally, cell fate determination of HSPCs was believed to be solely
stochastic.182 Although the exact mechanism of lineage commitment remains largely
unknown, emerging evidence suggests that a diverse set of determinants dictates HSC
fate. One example includes factors secreted by osteoblasts, osteoclasts, endothelial and
stromal cells, and other cell types within the endosteal and perivascular niches. These
secretions influence both proliferation and differentiation of HSPCs. We also know that
once a cell becomes a MPP, it loses the ability to self-renew and commits to the path of
differentiation, either becoming a CLP or CMP.
Lymphoid commitment
The oligopotent progenitor that gives rise to lymphocytes, the CLP, originates from
the Lin-cKit+Sca-1- (cKit+) progenitor population and can be further distinguished by high
expression of IL-7R.183 IL-7 is a cytokine responsible for T and B cell development,
maturation, and proliferation.184 There are three main types of lymphocytes: B cells, T
cells, and NK cells. NK cells belong to the innate immunity family along with myeloid cells
and can rapidly respond to stressed cells or foreign material with a cytotoxic response. B
and T cells are solely responsible for adaptive immunity and rely on major
histocompatibility complex (MHC) and antibodies to mount a response to infection.
Antibodies are comprised of four distinct peptide chains, two “heavy” and two “light,” that
are linked by disulfide bonds. Each antibody is composed of a constant portion and a
variable portion that recognizes a unique antigen produced by foreign material that
invades the host. B and T cells work in harmony to utilize antibodies produced by the B
cells to recognize harmful entities, orchestrate an immune response, and clear the host of
invading pathogens or abnormal cells.
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B lymphoid
B cells can be split into two class: B1 cells that originate from early progenitors in
the fetal liver and remain as a self-renewing population within the BM, and B2 cells that
come from BM precursor cells and complete the process of maturation within the
spleen.185 This section will focus on B2 lymphocyte maturation and function, as they are
the predominant B cell in adults. B cells are responsible for the humoral, or antibodymediated, response to antigens encountered within the host organism.
Development begins in the BM where the CLP acquires expression of the cell
surface marker B220 and begins the process of antibody production by undergoing V(D)J
(variable-diversity-joining) recombination of the heavy chain to produce first pre-pro-B
cells followed by pro-B and pre-B cells in a process known as positive selection.186 These
earliest B cells have a very short half-life and are particularly susceptible to a process
known as negative selection, or apoptosis that occurs upon B cell receptor (BCR)
stimulation of the newly formed IgM antibodies.187 The inefficiency of this system allows
for exclusion of auto-reactive antibodies and selectivity of the ones with the strongest
reaction. B cells that successfully produce antigen-reactive antibodies then migrate out of
the BM into circulation where they become transitional B cells that home to the spleen for
the culmination of the maturation process.188 Though the BM produces approximately 2 x
107 pro-B cells each day, only about 10% will successfully migrate to the spleen.
Within the spleen, transitional B cells can become one of two mature B cells
dependent upon how strongly they react with their antigen. B cells originating from the
marginal zone have polyreactive antibodies, are the main producers of IgM, and can act
in a T cell dependent or independent fashion.189 The follicular zone of the spleen gives
rise to the majority of the monoreactive plasma cells. After phagocytosing the antigen, the
follicular B cell will present the antigen to CD4+ T cells (helper T cells). Once a CD4+ T cell
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recognizes the antigen via MHC class II interaction, the follicular B cell will be stimulated
to return to a primary follicle and create a germinal center. Within the germinal center, the
follicular cell will rapidly divide and create antibodies with higher affinity to the antigen via
self-mutations. During the self-mutation process, the antibody classes will be changed so
that IgG, IgE, and IgA antibodies are produced. Of these mature antibodies, IgG
antibodies are primarily found in the blood plasma. IgA antibodies typically reside in
mucosal surfaces as a barrier to prevent foreign material from entering the body. IgE are
most well known for their role in allergies though they are also important for protection
against protozoan parasites.
B cells express all five isotypes of antibody (IgM, IgD, IgG, IgA, and IgE) and can
generate long-term memory B cells and short-term plasma cells.185 B cells interact with T
cells in a variety of ways: they can take on an antigen-presenting or costimulatory role that
activates T cells or they can release cytokines (particularly IL-6 and IL-10) that either
stimulate or inhibit T cell response.190 Together these two types of lymphocytes coordinate
a specific and aggressive reaction against harmful pathogens and cells to protect the host
organism.
T lymphoid
Progenitor cells that migrate to the thymus lose the ability to differentiate into B
cells and become restricted to the T cell lineage.119 These earliest T cells lacking
expression of CD4 and CD8 have been termed double negative cells and progress
through a variety of maturation steps.191 During the important phase of cellular
development, the immature T cells begin to produce T cell receptor (TCR) complexes that
eventually lead to the expression of CD4 and CD8 at the cell surface, making them double
positive. Double positive cells are the first to express complete αβTCR transmembrane
receptors that, similarly to BCRs, have a diverse set of unique structures enabling them
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to recognize numerous MHC-bound antigens. To avoid autoimmune disorders, T cells
undergo a strict selection process to eliminate TCRs that recognize self-MHC
molecules.192 Once the appropriate TCRs have been selected, T cells continue to mature
as they undergo both positive and negative selection to become restricted to a single
positive CD4 or CD8 state.193
CD4+ helper T and regulatory T cells
The process of CD4- or CD8-lineage specification is a highly consistent process in
which signaling by MHC class II molecules induces CD4+ differentiation and MHC class I
molecules specify CD8+ T cells.194 CD4+ cells are termed helper T cells, whereas CD8+
cells are cytotoxic T cells. When a naïve helper T cell encounters an MHC II-bound
antigen, it is activated and begins the release of cytokines that stimulate the adaptive
immune response.195 The response of activated helper T cells is a critical step in initiating
the immune system but aberrant activation can lead to inappropriate inflammation and
thus helper T cells are carefully controlled by regulatory T cells.196 Neither helper T nor
regulatory T cells play a direct role in elimination of compromised cells and pathogens,
instead that role is filled by the cytotoxic T cells.
CD8+ cytotoxic T cells
The CD8+ cytotoxic T cells recognize MHC I-bound antigens and are primed to kill
infected or malignant cells through one of three pathways. The first is through expression
of the Fas ligand that binds to the Fas receptor (CD95) on the target cell, triggering
caspase-mediated apoptosis.197 The second involves the release of granzymes and
perforin pre-packaged in secretory lysosomes into the intracellular space; these agents
are highly toxic and induce cell death.198 Unlike the first method, this one is only indirectly
specific to the target cell and has the potential to affect normal, healthy tissue. To prevent

43
harm to uninfected cells, the cytotoxic T cells control the release of the lysosomes
specifically and exclusively to the cell membrane directly adjacent to the target cell. This
prevents diffusion and concentrates the toxic materials so that they are specific to the
target cell. The cytotoxic agents induce cell death through caspase-mediated and
caspase-independent pathways.199 The third and final mechanism is through the release
of TNFα, that triggers the classical apoptotic caspase cascade, and IFNγ that causes the
target cells to express more Fas receptor and MHC class I antigen-presenting molecules
at the cell surface. This, in turn, also increases Fas-mediated apoptosis.200 This final
method of cytotoxicity does not require direct cell-cell contact like the first two methods,
rather the cytokines produced will affect the target cell and distant cells alike. Together the
B and T cell adaptive immunity generates a specific and aggressive immune response
that requires time to fully develop. To mediate a faster, though more generic response,
the immune system has also developed innate immunity primarily made up of myeloid
cells.
Myeloid commitment
The progenitor cells that give rise to myelocytes and erythrocytes were first
described by Akashi et al. in 2000. As with the CLP population, the CMPs come from the
cKit+ progenitor cells but can be further defined using the cell surface markers CD34 and
CD16/32 (also known as FcγR). Recent work provides evidence that commitment of an
MPP to become a CLP or CMP is not bimodal but rather CMPs develop when the
progenitor population loses the potential for lymphoid commitment.201 Unlike the CLPs that
comprise a more homogenous pool of progenitor cells, there are distinct groupings within
the cKit+ population with distinct differentiation capabilities. The first group,
CD34+CD16/32lo, is the most undifferentiated and the cells are true CMPs that can give
rise to a mix of myeloid cells.202 The second group, CD34+CD16/32hi or GMP, produces
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only macrophages or granulocytes; the third and final group, CD34+CD16/32lo or MEP, is
restricted to production of only megakaryocytes and erythrocytes.202 These progenitor
cells can also be subdivided based on transcription factor activity using a complex and
comprehensive set of gene expression profiles.203 Collectively, these cells make up the
innate branch of the immune system and are the first line of defense against invading
microbes. Myelopoiesis occurs in response to infection to produce a large number of shortlived immune cells.204 The myeloid branch of hematopoiesis contains four types of cells:
granulocytes, monocytes, megakaryocyte, and erythrocytes that will be discussed herein.
Granulocytes
Granulocytes are named and distinguished by the presence of granules within the
cytoplasm. There are three types of granulocytes: neutrophils, eosinophils, and basophils.
Of these, neutrophils are the most common and, indeed, the most abundant leukocyte
comprising > 50% of the WBCs.205 These cells are known for their ability to phagocytose
foreign matter such as bacteria and fungus. Neutrophils are typically the first responders
to sites of inflammation and have high sensitivity to chemoattractants such as IL-8.206
Despite, or perhaps because of their ability to quickly react to inflammation, neutrophils
are very short-lived, with a life-span of approximately 24 hours.207 Eosinophils and
basophils play similar roles and each comprise only a small portion of the total blood cells
(~ 1% and < 1%, respectively).208 Each was initially identified and named for its affinity
either for a basic (basophilic) or acidic (eosinophilic) dye. Eosinophils are known for their
primary role in host defense whereas basophils function mainly in allergic inflammation
due to the production of histamine.209,210 Both cell types participate in the adaptive immune
response by influencing the activation of T cells through the production and secretion of
TH2-inducing cytokines such as IL-4 (eosinophil) and IL-3 (basophil).211,212 Eosinophils
have an additional role in adaptive immunity by producing IL-5 to influence B cell humoral
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response.213 Perhaps the most interesting and unique aspect of eosinophils is their ability
to make mitochondrial DNA net traps that capture and immobilize foreign particles.214
Monocytes
Monocytes also stem from the GMP population and are distinguished by their lack
of cytoplasmic granules and unilobar nuclei. Monocytic versus granulocytic differentiation
is largely determined by expression of the transcription factor PU.1, where variations in
expression drive the progenitor cell toward specific lineages.215 Monocytes can be defined
as circulating phagocytic immune precursor cells to macrophages, of which there are three
distinct types in humans.216 Classical monocytes make up the majority of the monocytic
population, and are the most undifferentiated and proliferative of the three groups.217 The
non-classical monocytes are the most differentiated and mature of the group.218 The
intermediate monocytes represent a transitional state between the classical and nonclassical monocytes, though they tend to be more similar to the non-classical group.217 In
general, monocytes are cells primed to further differentiate and acquire macrophage-like
phenotypes that resolve sources of inflammation.
Macrophages are defined as tissue-resident phagocytic cells, of which there are
two types: tissue resident and inflammatory.216 Under conditions of inflammation,
monocytes quickly migrate to affected tissues where they transform into inflammatory
macrophages to combat the foreign material.219 The quick maturation of the primed
monocytes already in circulation allows for a rapid influx of macrophages without
necessitating passage through the cell cycle to increase numbers. These newly developed
macrophages assist the second group, the tissue-resident macrophages, in fighting off the
disease through phagocytosis and enzymatic lysis.220 The interplay and differences
between these two types of macrophages remains largely unknown and further evidence
is required to clearly distinguish between mature inflammatory macrophages and their
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tissue-resident counterparts. It was originally thought that all macrophages were derived
from circulating monocytes but studies have shown that the tissue-resident subset actually
comes from primitive embryonic macrophages and are capable of self-renewal.221 These
macrophages also exhibit distinct phenotypes that vary between tissues of residency,
likely due to the differences in microenvironment from one tissue to another. 222 Tissueresident macrophages are an important component of the innate immune system as they
are typically the first line of defense and can play a role in coordinating the response of
other immune cells like the granulocytes and NK cells.
Megakaryocytes and erythrocytes
Neither megakaryocytes nor erythrocytes belong to the WBC family but both
belong to the myeloid family of hematopoietic cells. The branching time at which progenitor
cells commit to the MEP pathway is a point of debate among experts and experimental
evidence has produced two different models. The classical model holds that the point of
divergence occurs after the MPP has committed to the CMP branch and that further
differentiation produces GMPs or MEPs.223 More recently, evidence has shown that the
divergence might occur at an earlier point or that perhaps commitment can occur at
multiple points along the differentiation pathway.224,225
Megakaryocytes are the largest and rarest of the hematopoietic cells and reside
primarily within the adult BM.226 The process of megakaryopoiesis, or the development of
platelets, is indispensable for a variety of hematopoietic processes including wound
healing and innate immunity. Maturation begins with a series of DNA replications lacking
cytokinesis, a process called endomitosis, that result in a large multilobed nucleus with
DNA ranging anywhere from 8N to 128N.227 Maturation continues as the megakaryocyte
cytoplasm becomes increasingly granulated and begins to form long branching processes
that extend into the blood vessels. Fission occurs at the ends of the branches, budding off
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cell fragments containing granules and organelles from the cytoplasm to form enucleated
proplatelets.228 Complete maturation takes place in the bloodstream to form platelets that
function primarily to prevent bleeding by forming aggregates at sites of blood vessel injury.
One of the most important findings involving megakaryocytes was the discovery of TPO,
the cytokine that directs megakaryopoiesis and platelet formation.229 Since its discovery,
TPO mimetics have been developed and used extensively for the clinical treatment of
thrombocytopenia.230
Erythrocytes, also known as RBCs, are small, red, enucleated disc-shaped cells
whose primary function is transporting oxygen to all tissues within an organism, though
they are involved in other oxygen-regulated processes.231 These are the most abundant
cell in the human body and about 2 x 1011 new erythrocytes are produced on a daily
basis.232 Erythrocytes contain millions of iron metalloproteins called hemoglobin that exist
in an oxygenated (up to four oxygen molecules) or deoxygenated state that allow
erythrocytes to deliver oxygen to tissues distant from the lungs.233 Primitive erythrocytes
are the first hematopoietic cell to emerge from the yolk sac during embryonic development,
stemming from erythroid or erythromyeloid progenitors capable of self-renewal. These
early RBCs are distinct in that they are large and nucleated, compared to the small
enucleated definitive erythrocytes that begin to populate the blood in the later stages of
gestation.234 These primitive erythroblasts are important for embryonic survival because
they contain fetal hemoglobin, which has a higher affinity for O2 than adult hemoglobin,
facilitating the transmission of oxygen from maternal to fetal circulation. 235,236 Following
the development and migration of HSCs to the BM, definitive erythrocytes begin to
differentiate from HSCs like all other hematopoietic lineages.237 Just as megakaryocyte
development is controlled by TPO, erythrocyte development is regulated by EPO.
Recombinant human EPO has been largely used as a first-line therapy in the treatment of
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many diseases affecting RBC development.238 Along with thrombocytopenia, anemia is
one of the most common hematologic disorders. It can result from insufficient intake of
iron but more commonly results from anemia of inflammation, a side-effect of disorders
like renal failure, autoimmune disease, and some cancers.239
Hematopoiesis: Conclusion
One area of interest is the function of the immune system in the context of cancer.
Cancer is a unique disease in that it originates from cells belonging to the host organism
that express self-cell surface markers that prevent immune response. Thus, tumorigenic
cells often do not activate the immune system or, if they do, have developed methods of
evading, negating, or preventing immune response. Many current cancer therapeutic
developments seek to harness the power of the innate and adaptive immune system to
fight cancer without compromising the host by initiating an autoimmune response.
Unlocking the ability of these cells and stimulating them to attack tumors provides the
potential to eliminate the disease and prevent its recurrence by retaining memory B cells
primed to recognize future outgrowth.
While often referred to as separate responses, innate and adaptive immunity are
interlinked and work together in a perfectly choreographed manner to defend the host
organism. The innate immune system utilizes pattern-recognition receptors to identify
conserved pathogenic features and patterns to induce the inflammatory response.240 The
type of pattern encountered by the innate immune cell indicates to the adaptive immune
system which antigen to use for antibody development and instructs on the type of
infection encountered in order to mount the correct immune response.241 Innate immune
cells can also recognize a lack of self-characteristics to discriminate between host-derived
and foreign pathogens or stressed cells in order to tailor the adaptive response to the
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correct targets.242 By working in conjunction, these two branches of the immune system
provide a highly efficient defense against harmful pathogens and abnormal cells.
Immune cells represent an important and clinically relevant class of cells that has
broad implications in the pathophysiology of disease. The role these cells play in allaying
microbial and viral infections has been extensively studied and new research continues to
reveal the multifaceted functions of this intricate and indispensable system. Each aspect
of hematopoiesis, from maintaining quiescence of stem cells to cell cycle regulation to
differentiation and finally to apoptosis in aged or flawed cells, must be precisely organized.
Dysregulation at any one of these stages can result in fatal errors. As previously
discussed, the UPS coordinates the expression of proteins that regulate development,
quiescence, cell cycle, differentiation, cellular homeostasis, and apoptosis. The E3
ubiquitin ligase components of the UPS are integral to determining protein expression and
the coordination of these pathways. One E3 ligase differentially expressed in the
hematopoietic system is the protein FBXO9.243
F-Box only protein 9 (FBXO9)
FBXO9 is a member of the SCF family of E3 ligases containing the characteristic
F-box domain and a protein-binding tetratricopeptide repeat (TPR) domain. It is a highly
conserved gene and more highly conserved protein with nearly identical homology in the
F-box and TPR domains across a variety of species. FBXO9 is composed of 12 exons
that correspond to 447 amino acids in humans or 13 exons and 437 amino acids in mice.88
The majority of the TPR domain is contained within exon 4 while the F-box domain begins
at the end of exon 6 and continues through exon 7 to the beginning of exon 8 (Figure 5A).
This arrangement makes FBXO9 somewhat unique within its family as the majority of Fbox proteins have an F-box domain proximal to the C-terminus and a protein-binding
domain at the N-terminus.244
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As with other F-box proteins, FBXO9 binds to the SCF RING E3 ligase complex
via the F-box domain and binds phosphorylated substrate proteins at the TPR domain. As
was previously mentioned, in MM FBXO9 has been shown to bind to and ubiquitinate
TEL2 and TTI1 within mammalian target of rapamycin complex 1 (mTORC1), tagging
them for degradation at the proteasome. This degradation shifts signaling to mTORC2
and promotes tumor cell survival and proliferation.91,159 As with most F-box proteins,
FBXO9 ubiquitinates substrates in a phosphodegron-dependent manner. In the case of
TEL2 and TTI1, casein kinase 2 is responsible for phosphorylation at the motif SXXD/E
which occurs at S485 in TEL2 and S828 in TTI1.159 Outside of its function in MM, the role
of FBXO9 in both normal and malignant hematopoiesis has yet to be studied.
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Chapter 2 Results
Confirmation of FBXO9 mRNA expression in hematopoietic populations
We began our analysis of Fbxo9 by confirming expression variations seen in the
hematopoietic system.243 We analyzed different hematopoietic populations, including
progenitors and mature cells, isolated from BM of a healthy WT mouse and found that
Fbxo9 is most highly expressed in ST-HSCs and LT-HSCs as well as some myeloid
lineages (Figure 5B). These data are consistent with previously published datasets
obtained by microarray expression profiling of HSCs and their progeny (GSE14833 and
GSE6506). Elevated expression in the primitive populations makes the study of FBXO9
more intriguing when considering its potential role in the maintenance of HSPCs and in
malignant transformation, as many oncogenic cellular alterations occur in the stem and
progenitor populations.
Generation of conditional knockout of Fbxo9
To provide a model for studying the role of Fbxo9 in the hematopoietic system, we
generated a tissue-specific conditional knock out (cKO) mouse model. Using the EasiCRISPR method, we introduced LoxP sites flanking Fbxo9 exon 4, which contains the
majority of the TPR domain (Figure 6A).245 The targeted mouse was bred with an Mx1-cre
mouse, a model in which cre recombinase is expressed throughout all stages of
hematopoiesis, including the stem cells, upon administration of Polyinosinic:Polycytidilic
acid (Poly(I:C)). In mice expressing the floxed Fbxo9 and Mx1-cre alleles, the cre
recombinase is activated through three subsequent bi-daily injections to delete Fbxo9
exon 4.246 Loss of exon 4 upon expression of cre recombinase results in the ablation of
TPR binding and initiates a frame-shift mutation leading to the additional loss of the F-box
domain and a premature stop generating a protein with only 166 amino acids. This
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mutation was confirmed by PCR and sequencing in Fbxo9-/- BM (Figure 6B). While not a
complete knockout of the gene, the resulting truncated protein lacks both domains critical
for its E3 ligase function (Figure 5A).
We confirmed the genotypes of the mice by PCR and further analyzed Fbxo9
expression using qRT-PCR on BM derived from replicate Fbxo9+/- and Fbxo9-/- mice
compared to Fbxo9+/+ (Figure 6C-D). The expression in the cKO groups was reduced
~55% in Fbxo9+/- and ~80% in Fbxo9-/-. Due to lack of a commercially available antibody
recognizing mouse FBXO9, we transfected tagged Fbxo9 mutant plasmids into 293T cells
including a mutant lacking exon 4 (without inclusion of the introns) to mimic the mutation
that arises in the mouse model following Poly(I:C) injection (Figure 5A). Mutants lacking
the F-box or TPR domains showed a slight decrease in molecular weight whereas the
mutant lacking bases corresponding to exon 4 showed a much greater decrease in
molecular weight (Figure 6E). The band size correlated with the anticipated molecular
weight of a protein arising from cKO cells predicted to have a frameshift mutation leading
to loss of the F-box domain and a premature stop. This evidence indicates that deletion of
exon 4 in our mouse model results in a truncated protein lacking the TPR and F-box
domains.
Fbxo9 deletion leads to alterations in HSPC populations
To study the role of Fbxo9 in normal hematopoiesis, we deleted Fbxo9 from cKO
mice by three sequential injections with Poly(I:C). Analysis of the BM four weeks postPoly(I:C) revealed a slight, though not significant, decrease in total cell number upon
knockout of Fbxo9 (Figure 7A). Though we observed no difference in the distribution of
mature hematopoietic populations (myeloid, T lymphoid, or B lymphoid), the Lin- cells,
which include HPSCs, showed a moderate decrease in total number upon loss of Fbxo9,
corresponding to the marginal decrease in total cell number (Figure 7B-C, Table 3).
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Further analysis of the HSPCs revealed that Fbxo9 cKO did not affect the stem and early
progenitor cells (LSKs) but caused a decrease in the cKit+ progenitor population due to a
loss of MEPs (Figure 7D-F). To determine whether loss of Fbxo9 alters differentiation of
HSPCs, we carried out a colony forming cell assay and found that the proliferative capacity
of LSKs derived from all three genotypes remained unaltered in response to cytokine
stimulation (Figure 8A). We further analyzed these populations for apoptosis and cell cycle
alterations and found that Fbxo9 cKO does not alter survival or cell cycle progression of
Lin-, cKit+, or LSK cells (Figure 8B-D).
Transplants – competitive and normal
To analyze the effect of loss of Fbxo9 on the ability of stem cells to engraft and
proliferate, we utilized BM isolated from cKO mice in two different types of
transplantations. The first transplantation assay involved the direct transplantation of cKO
and WT BM into lethally irradiated syngeneic hosts. If the host mice had altered cellular
composition, did not survive, or had reduced lifespan, we could conclude that Fbxo9 is
necessary for HSC engraftment and normal reconstitution in the BM. However, following
transplantation we did not see any shifts in mature hematopoietic populations nor did we
observe a difference in survival of host mice (data not shown).
To further interrogate this system, we also conducted a competitive repopulation
assay in which we injected lethally irradiated syngeneic hosts with BM derived from
Poly(I:C)-treated CD45.2 Fbxo9+/+ or Fbxo9-/- mice in conjunction with BM from a CD45.1
WT mouse (Figure 9A). Injecting a 50/50 mix of WT and Poly(I:C)-treated BM allowed us
to determine whether Fbxo9 cKO affects cycling time or differentiation of stem cells. When
we transplanted the mixed BM into the hosts, we observed no difference in distribution of
CD45.1 vs CD45.2 between the cKO and WT groups and found that loss of Fbxo9 neither
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impairs nor enhances the ability to engraft and give rise to mature hematopoietic cells
(Figure 9B).
Stress Hematopoiesis
The transplantation experiments we conducted primarily informed about the STHSC population and their ability to repopulate the BM and provide radioprotection to the
host mouse. To interrogate the role of Fbxo9 in recovery following hematopoietic stress,
we treated WT and cKO mice with weekly injections of 5-fluorouracil (5-FU). The primary
mechanism of action for 5-FU involves the inhibition of thymidylate synthase, an enzyme
that

catalyzes

deoxyuridine

monophosphate

conversion

to

deoxythymidine

monophosphate, a nucleotide component of DNA. Thymidylate synthase inhibition causes
increasing levels of deoxyuridine monophosphate and subsequent DNA damage leading
to cell death.
For the purpose of our investigations, we were particularly interested in the
myeloablative ability of 5-FU treatment. By purging the blood of mature WBCs, 5-FU
treatment instigates cycling of the HSCs to repopulate the system with mature
hematopoietic cells. Subsequent weekly injections of 5-FU consistently eliminate the
mature hematopoietic cells and cause the stem cells to continuously re-enter the cell
cycle. Constant mobilization of the ST-HSCs leads to cell cycle progression of the LTHSCs and eventually results in exhaustion of the total stem cell pool and death of the
treated mouse. Comparison of 5-FU treated Fbxo9-/- and Fbxo9+/+ mice would determine
whether cKO affects the LT-HSCs. We injected Poly(I:C)-treated Fbxo9-/- and Fbxo9+/+
mice with 5-FU on a weekly basis and observed the survival time of the mice in each
cohort. We found that Fbxo9 cKO does not alter the survival curve either positively or
negatively (Figure 10). This indicates that FBXO9 alone does not maintain the LT-HSC
pool through regulation of proliferation or quiescence.
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Mass spectrometry
Since Fbxo9 had higher expression in the HSC population, we utilized a mass
spectrometry (MS)-based approach to identify potential targets in normal vs stress
hematopoiesis. To analyze the differences in protein expression between Fbxo9 cKO and
WT mice with and without 5-FU treatment, we labeled proteins isolated from the BM of
Fbxo9+/+ and Fbxo9-/- mice prior to and one week following 5-FU treatment with tandem
mass tags (TMT). We began by isolating proteins from the pelleted cells, labeling them
with TMT tags, combining equal proportions, and analyzing them by MS (LC-MS/MS;
Figure 11A). Mass spectrometry identified 9253 unique peptides corresponding to 2326
proteins, 1671 of which were quantified, and 306 of which were up- or downregulated (fold
change ≥ 1.3 or ≤ 0.7; Figure 11B).
Analysis of four different sample groups necessitated a variety of comparisons to
identify the proteins of interest. The purpose of the MS analysis was to identify proteins
altered in the cKO group after 5-FU treatment. To isolate proteins specific to this group we
carried out multiple comparisons summarized in Table 4 (Figure 11C).
The 38 proteins identified in the Fbxo9-/-5FU / Fbxo9+/+ cohort exclude any protein
expression alterations due to loss of Fbxo9 (overlap with Fbxo9-/-5FU / Fbxo9-/- or Fbxo9/-

/ Fbxo9+/+) or due to treatment with 5-FU (overlap with Fbxo9-/-5FU / Fbxo9+/+5FU or

Fbxo9+/+5FU / Fbxo9+/+). The resultant proteins are summarized in Table 5. Identification
by MS does not prove a direct relationship between FBXO9 and any of the differentially
expressed proteins but analysis of the pathways those proteins participate in indicates the
mechanisms potentially regulated by FBXO9. A gene ontology term search of the up- and
downregulated proteins in the Fbxo9-/-5FU group compared to the WT controls reveals the
biological processes in which these differentially expressed proteins participate (Figure
12. The most common pathways in which these proteins participate (both up- and
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downregulated) include metabolic processes (GO: 0008152), cellular processes (GO:
0009987), and localization (GO: 0051179). Proteins with differential regulation in 5-FUtreated Fbxo9-/- mice include components of the proteasome activator subunit (PSME). As
was previously discussed, the UPS is known to play a critical role in processes important
to HSC biology like quiescence and differentiation. Additional differentially regulated
proteins include two cytochrome c oxidase subunits, acetyl-CoA acetyltransferase,
succinate dehydrogenase, and an isocitrate dehydrogenase subunit. These proteins
participate in the canonical glycolysis-Krebs cycle-oxidative phosphorylation pathway that
provides cells with energy in the form of ATP. Metabolic regulation within HSCs plays a
role in balancing self-renewal and differentiation to maintain both the stem cell pool and
populate the BM and blood with mature hematopoietic cells. Considering that treatment
with the myeloablative 5-FU provides a method of evaluating alterations occurring in the
HSPCs upon cKO of Fbxo9, we propose that the aforementioned mentioned pathways
represent those most likely regulated by FBXO9 in HSPCs.
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Chapter 2 Conclusion
The evidence presented herein begins to uncover an intriguing role for FBXO9 in
hematopoiesis, particularly within the HSPC population. Despite high expression in HSPC
populations, loss of Fbxo9 alone does not adversely affect HSPC quiescence,
proliferation, or differentiation. Though no direct effect was observed in normal
hematopoiesis, we cannot rule out the possibility of a secondary mechanism that
compensates for the loss of Fbxo9. This implies that defects leading to a loss of FBXO9
function could prove detrimental to homeostasis within the HSPC pool should a second
deleterious mutation be acquired. Additionally, the redundancy indicates that FBXO9 may
regulate pathways critical for survival and the maintenance of normal hematopoiesis.
We found that Fbxo9 is most highly expressed in ST- and LT-HSCs and that its
loss led to a marginal decrease in total cell number and a reduction in cKit+ progenitor
cells. MS analysis revealed that the proteins altered in the HSPCs by loss of Fbxo9 are
enriched for proteins involved in cellular metabolism. Previously, metabolism and
mitochondrial function have been linked to HSPC functionality and have been shown to
directly control the fate of HSCs.247 A recent study by Yang et al. revealed that mutations
affecting epigenetic regulation in the hematopoietic system lead to dysregulation of adult
HSCs. Furthermore, they found that impaired glycolysis and mitochondrial function had
the potential to adversely affect HSC maintenance and disable HSC activation.248
Metabolism is tightly regulated in the HSC pool, often responds to changes in BM niche
signaling, and is likely regulated by the UPS and expression of FBXO9.249
Metabolic plasticity within HSCs is responsible for maintaining the balance
between quiescence, self-renewal, and differentiation. HSCs remain in a quiescent, selfrenewing state when undergoing glycolysis and fatty acid metabolism and shift to a more
proliferative state upon induction of mitochondrial respiration.250 The results described
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herein indicate that FBXO9 plays a role in maintaining the balance between quiescence
and differentiation through regulation of metabolism. Additionally, disruptions in
metabolism within the HSCs can lead to metabolic shifts that cause leukemia or other
hematologic malignancies.251 These results indicate that FBXO9 likely plays a critical,
though potentially redundant, function in HSPCs and a more complete understanding of
its precise role could lead to a more comprehensive understanding of the pathways
regulating HSPC homeostasis.
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Figure 4 Schematic of hematopoiesis. Overview of hematopoietic differentiation
beginning with LT-HSCs and continuing through complete maturation of the lymphoid and
myeloid branches.
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Figure 5 Fbxo9 has differential expression across hematopoietic lineages. A
Schematic of full length FBXO9 as well as ΔF-box, ΔTPR, and ΔExon4 mutants
(crosshatch denotes frameshift mutation, numbers indicate amino acid position). B
Analysis of Fbxo9 expression in WT murine hematopoietic lineages shows expression
differences in a variety of hematopoietic lineages (TBM, total bone marrow; LSK,
Lin−cKit+Sca-1+;
1+CD150−CD48−;
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62
Figure 6
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Figure 6 Generation of conditional Fbxo9 knockout mouse model. A Introduction of
LoxP sites flanking exon 4. B Amino acid translation of sequenced cDNA from Fbxo9+/+
and Fbxo9-/- mice. C Genotyping PCR for introduction of LoxP sites, presence of cre and
the Cbfb+/56M allele, loss of exon 4, and expression of Cbfb-MYH11 fusion gene. D qRTPCR of Fbxo9 exon 4 and exon 2-3 following injection with Poly(I:C). E Western blot of
overexpressed flag-tagged FBXO9 with various deletion mutations
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Figure 7
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Figure 7 Loss of Fbxo9 modestly alters murine HSPCs. A Cell counts from BM
extracted from the right femur of sacrificed mice. B Cells count of Lin- cells. C Cell counts
of mature myeloid cells (all Gr1+ and all Mac1+), B cells (B220+), and T cells (all CD4+ and
all CD8+). D Cell counts of cKit+ and LSKs. E Cell count of LSK populations: LT-HSC, STHSC, MPP (Lin−cKit+Sca-1+CD150−CD48+), and MPP2 (Lin−cKit+Sca-1+CD150+CD48+). F
Cell counts of cKit+ populations: MEP, CMP, and GMP (for all data shown, bar graphs are
mean ± standard deviation, n = 3, * p < 0.05, ** p < 0.01, **** p < 0.0001).
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Figure 8
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Figure 8 Loss of Fbxo9 does not affect HSPC function. A Bar graph of colonies per
10,000 cells plated in methyl cellulose (GM, granulocyte-macrophage; GEMM,
granulocyte-erythrocyte-monocyte-megakaryocyte; E, erythroid). B Bar graph showing
the percentage of cells in G0-G1 and S-G2-M. C Bar graph of live and dead cells. D Flow
cytometry gating strategy for isolating LSK and cKit+ populations form TBM and analyzing
for cell cycle stage (all graphs are mean ± standard deviation, n = 3).
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Figure 9
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Figure 9 Fbxo9 cKO neither enhances nor impairs the ability of the HSCs to
repopulate the BM. A Schematic of competitive repopulation strategy. B Cell composition
of Fbxo9+/+ and Fbxo9-/- cells following competitive repopulation transplantation.
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Figure 10
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Figure 10 Fbxo9 cKO does not provide protection or enhance susceptibility of mice
to myeloablative therapy. A Survival curve of 5-FU treated mice.
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Figure 11 Mass spectrometry identifies proteins differentially expressed in stress
hematopoiesis upon cKO of Fbxo9. A Schematic of preparation for TM MS using BM
isolated from the indicated groups. B Quantification of the identified peptides and proteins.
C Venn diagram illustrating the differentially expressed proteins in each cohort.
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Figure 12
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Figure 12 Fbxo9 cKO alters the proteomic landscape of HSPCs. A Pie charts
illustrating which pathway are altered in 5-FU-treated Fbxo9-/- HSPCs, both up- and
downregulated.
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Table 2 Subdivision of murine HSPCs (LSKs) using SLAM family cell surface
markers
Class
LT-HSC-1
LT-HSC-2
ST-HSC-1
ST-HSC-2
ST-HSC-3
MPP-1
MPP-2

Cell surface
markers
CD150+CD48CD229-CD244CD150+CD48CD229+CD244CD150-CD48CD229-CD244CD150-CD48CD229+CD244CD150-CD48CD229+CD244+
CD150-CD48+
CD150+CD48+

Differentiation and self-renewal posttransplant
Mostly myeloid, primarily quiescent
Mostly lymphoid, more actively dividing
Transient multilineage, self-renew for 8 weeks
Transient multilineage, self-renew for 6 weeks
Transient multilineage, self-renew for 4 weeks
Multipotent, myeloid and/or B cell
Megakaryocyte or megakaryocyte-erythroid
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Table 3 Complete blood counts for mice sacrificed three weeks post-Poly(I:C)
Fbxo9+/+

Fbxo9+/-

Fbxo9-/-

WBC

21.86 ± 6.02

14.10 ± 12.05

21.44 ± 5.43

Monocyte

1.12 ± 0.32

0.73 ± 0.73

1.08 ± 0.40

Eosinophil

1.03 ± 0.48

0.38 ± 0.36

0.86 ± 0.69

Neutrophil

4.97 ± 1.67

2.37 ± 2.23

3.79 ± 1.65

Basophil

0.22 ± 0.12

0.08 ± 0.08

0.17 ± 0.16

RBC

8.69 ± 1.37

6.75 ± 3.72

7.52 ± 1.79

Platelet

456 ± 176

373 ± 211

307 ± 69

Counts for total WBCs, various myeloid lineages, RBCs, and platelets (mean ± 95%
confidence interval).
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Table 4 Number of differentially expressed proteins in stress hematopoiesis
Comparison
Fbxo9-/- / Fbxo9+/+
Fbxo9+/+5FU / Fbxo9+/+
Fbxo9-/-5FU / Fbxo9+/+
Fbxo9-/-5FU / Fbxo9+/+5FU
Fbxo9-/-5FU / Fbxo9-/Total

Total differentially
expressed proteins
31
137
206
110
164
648 (306 unique)

Proteins specific
to the group
6
25
38
18
24
111
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Table 5 Proteins up- and downregulated in Fbxo9-/-5FU mice
Symbol
ACAT1

Location
Cytoplasm

Type(s)
enzyme

RNF213

Cytoplasm

enzyme

HSPA5

Cytoplasm

enzyme

PDIA3

Cytoplasm

peptidase

ARMC10

Cytoplasm

other

NANS

Cytoplasm

enzyme

RAB11B

Cytoplasm

enzyme

RAC1

Plasma
Membrane

enzyme

CPNE2

Cytoplasm

other

COX4I1

Cytoplasm

enzyme

UGGT1

Cytoplasm

enzyme

PSME2

Cytoplasm

peptidase

ERH
COX6B1
PGAM1

Nucleus
Cytoplasm
Cytoplasm

other
enzyme
phosphatase

HIST1H4D
COX2

Nucleus
Cytoplasm

other
enzyme

POLA1
SDHB

Nucleus
Cytoplasm

enzyme
enzyme

Cdc42

Plasma
Membrane

enzyme

HSPBP1
BIN2

Cytoplasm
Plasma
Membrane

other
other

Function
catalyze the last step of
mitochondrial beta-oxidation
E3 ligase for FLNA and NFATC2
involved in non-canonical Wnt
signaling and angiogenesis
protein folding chaperone in the
endoplasmic reticulum lumen
catalyzes rearrangement of disulfide
bonds
may play a role in survival and
growth by suppressing p53
catalyze formation of Neu5Ac and
KDN
GTPase that regulates intracellular
membrane trafficking
membrane-bound GTPase involved
in secretion, phagocytosis,
polarization, adhesion, migration,
differentiation, and membrane
ruffling.
Ca-dependent phospholipid-binding
protein that participates in calciummediated intracellular processes
polypeptide chain of cytochrome c
oxidase
recognizes glycoproteins with minor
folding defects
implicated in immunoproteasome
assembly, required for efficient
antigen processing
possible cell cycle regulator
assists in COX dimerization
catalyze interconversion of
phosphoglycerate to
diphosphoglycerate
core component of nucleosome
catalyze reduction of oxygen to
water
catalyze DNA replication
component of succinate
dehydrogenase in the electron
transport chain
membrane-bound GTPase involved
in polarization, microtubule
attachment to kinetochores, and
migration
inhibits HSPA1A chaperone activity
promotes motility and migration

Abundance
0.623
0.631

0.631
0.645
0.648
0.655
0.665
0.670

0.679

0.681
0.682
0.683

0.683
0.684
0.686

0.693
0.696
0.697
0.698

0.700

1.300
1.301
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APRT

Cytoplasm

enzyme

SGTA

Cytoplasm

other

PSME3

Cytoplasm

peptidase

IDH3B

Cytoplasm

enzyme

IARS

Cytoplasm

enzyme

YBX3

Nucleus

MRTO4

Cytoplasm

transcription
regulator
other

RPS13
LARS

Cytoplasm
Cytoplasm

other
enzyme

KPNA2
NSUN2

Nucleus
Nucleus

transporter
enzyme

NASP

Nucleus

other

BSG

transporter

ETF1

Plasma
Membrane
Plasma
Membrane
Cytoplasm

IPO4

Nucleus

CAPRIN1

other
translation
regulator
transporter

catalyze salvage reaction that forms
AMP
binds misfolded proteins and
hydrophobic patches, targets to
endoplasmic reticulum or
proteasome
subunit of 11S proteasome
regulator
facilitate assembly and enzymatic
decarboxylation of isocitrate into
alpha-ketoglutarate
catalyze amino acid attachment to
tRNA
binds and represses GM-CSF
promoter
component of ribosome assembly
machinery
component of ribosome subunit
catalyze amino acid attachment to
tRNA
adapter protein for nuclear import
methylate RNA cytosine to 5methylcytosine in tRNA, mRNA, and
lncRNA
required for DNA replication, cell
cycle progression, and proliferation
role in targeting monocarboxylate
transporters to plasma membrane
regulate transport and translation of
certain proteins
directs termination of translation

1.302

nuclear protein import and nuclear
transport receptor

1.397

Upregulation ≥ 1.3-fold increase or downregulation ≤ 0.7-fold decrease

1.303

1.304
1.309

1.318
1.321
1.330
1.334
1.336
1.338
1.339

1.350
1.352
1.356
1.363
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CHAPTER 3:
FBXO9 IN MALIGNANT HEMATOPOIESIS
Portions of this chapter have been published as: Hynes-Smith, R. W. et al. Loss of
FBXO9 Enhances Proteasome Activity and Promotes Aggressiveness in Acute Myeloid
Leukemia. Cancers (Basel) 11, doi:10.3390/cancers11111717 (2019).
Acute Myeloid Leukemia
Acute Myeloid Leukemia is the most common form of acute adult leukemia and the
second most common form of childhood leukemia. The American Cancer Society
estimates that about 30% of all newly diagnosed leukemias will be AML, making it one of
the leading contributors to new diagnoses. Despite only one third of new cases being AML,
nearly half of leukemia-related deaths will result from AML.9 Additionally, these patients
have the lowest 5-year survival of all common leukemia subtypes at less than 27% and it
is the only common form of leukemia to have a higher mortality rate than new diagnoses
(Figure 13A).9 AML is characterized by the overproduction of immature myeloid blast
cells.252,253 Overgrowth of this population results in suppression of normal hematopoiesis
within the BM, consequently, patients suffer from thrombocytopenia, neutropenia, anemia,
and other blood and immune cell deficiencies.254 Specific, recurrent chromosomal
abnormalities, such as translocations and inversions, are often seen in AML and give rise
to oncogenic fusion proteins (Figure 13B).
Common chromosomal alterations and mutations
There are four common chromosomal abnormalities that give rise to AML. The first
is AML with t(8;21)(q22;q22). The RUNX1-ETO (also known as AML-ETO or RUNX1RUNX1T1) translocation gives rise to a fusion protein involving the transcription factor
RUNX1 and eight twenty one protein (ETO), a transcriptional repressor.255 This fusion
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protein binds RUNX1-mediated genes, thus repressing them and blocking myeloid
differentiation. The second is t(15;17)(q24;q21), the translocation characteristic of acute
promyelocytic leukemia. It results in the fusion of promyelocytic leukemia protein (PML)
and retinoic acid receptor α (PML-RARα), a transcriptional repressor that interferes with
differentiation, apoptosis, and self-renewal.256 The third group includes rearrangements
involving MLL (11q23). MLL, also known as histone-lysine N-methyltransferase 2A, alters
the epigenetic landscape of active promoter regions.257 Over 80 MLL fusions have been
identified, all of which drive initiation of an aggressive leukemia.258 The final subdivision
encompasses inv(16)(p13;q22) and t(16;16)(p13;q22) mutations that arise from an
inversion or translocation within chromosome 16. These cytogenetic abnormalities result
in the formation of the CBFB-MYH11 fusion in which the gene for CBFβ is linked to the
smooth muscle myosin heavy chain (SMMHC) gene, MYH11.259 The resulting CBFβSMMHC fusion protein alters activity of RUNX1, leading to a block in differentiation of
myeloid progenitor cells.260,261 In addition to the four mentioned herein, there are other less
common translocations and inversions characteristic of AML, some more common in
children or adults while others typically found in more specific patient subsets such as
those with trisomy or t-AML. Furthermore, patients can be classified as having a complex
karyotype in which multiple chromosomal rearrangements drive leukemia initiation.
Many genetic abnormalities give rise to AML but some patient tumors are found to
be cytogenetically normal. In these instances, leukemogenesis is instigated by mutations
that affect myeloid cell differentiation and proliferation, some of which are targetable. One
of the most commonly mutated genes is Fms-like Tyrosine Kinase 3 (FLT3) and its most
prevalent alteration involves an internal tandem duplication (FLT3-ITD). This mutation
promotes constitutive receptor activation and is associated with poor prognosis.262
Mutations in isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are associated with a
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more intermediate risk. These mutant proteins work by shifting metabolism to produce an
abundance of α-hydroxyglutarate, an oncometabolite that promotes tumorigenesis by
blocking

many

important

α-ketoglutarate-dependent

enzymes.263

Mutations

in

Nucleophosmin 1 (NPM1) are typically associated with a favorable prognosis. AMLassociated mutations result in loss of the NPM1 nuclear localization signal and
consequent accumulation in the cytoplasm.264 It has been shown to regulate the p53mediated tumor-suppressor pathway.265 DNA methyltransferase 3 alpha is also frequently
mutated in AML, leading to a reduction in de novo methylation that promotes
leukemogenesis.266 Less common AML-associated point mutations or deletions occur in
KIT, RUNX1, MLL, TP53, and TET2.
AML datasets
The study of human diseases, AML included, relies heavily upon patient-derived
samples analyzed to build patient datasets. These datasets contain information that allows
researchers to find correlations between disease and cellular alterations. This information
often includes clinical data such as gender, age, race, known mutations, stage at
diagnosis, time of survival, etc. Additional data of interest include sequencing or
expression analysis. The larger the dataset and the more information it contains, the more
useful it will be for guiding research. Most datasets, and in the case of AML all published
datasets, are comprised of RNA expression analysis as opposed to genomic/exomic or
proteomic data. Data from the latter analyses can be far more complicated to acquire and
analyze than transcriptomic data. For the study of AML, three main patient datasets exist:
the MILE study, TCGA adult, and TARGET pediatric dataset.
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MILE study
The Microarray Innovations in Leukemia (MILE) study is the largest publicly
available leukemia patient dataset (GSE13159).267 This study evaluated samples at the
time of diagnosis from patients with de novo AML, ALL, CML, CLL, or MDS and compares
them to healthy controls. The patients are mostly adult but some pediatric patient samples
were also collected. In total, over 3000 samples were analyzed across 11 different labs all
coordinated through the European LeukemiaNet. This study utilized 2096 of those patient
samples for an in-depth microarray analysis comparing 1480 distinct probes on a single
custom designed chip. The expression of each of the corresponding mRNAs was
correlated with patient diagnostic data including cytomorphology, cytogenetics, and
immunophenotyping. This dataset lacks patient clinical data such as age, ethnicity, and
time of survival making it impossible to conduct functional correlation studies. The MILE
study included two stages: the first as described above and the second to test the
diagnostic capability of this microarray-based assay. In stage two, 1152 patient samples
were blinded, analyzed by microarray, and classified based on the data collected in phase
one. Overall, the assay they developed provided 88.1% diagnostic accuracy when
comparing all 18 different leukemia subtypes and 91.5% when comparing only the 14
acute leukemias. While its use as a diagnostic assay remains inferior to other tools such
as flow cytometry and cytogenetics, the samples collected provide a large database of
RNA expression correlated with leukemia subtype.
TCGA adult AML dataset
In 2013, researchers with The Cancer Genome Atlas (TCGA) analyzed 200 adult
de novo AML patient samples to determine whether they could further stratify prognosis,
particularly among the intermediate risk group.268 To this end, they analyzed 50 samples
using whole-genome sequencing (WGS), 150 samples with whole-exome sequencing,
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and all 200 with RNA/microRNA sequencing and DNA methylation. Each sample included
the primary tumor as well as a paired normal skin sample to use as a control and to identify
germline variants. This dataset includes DNA mutation and methylation as well as RNA
expression data that can be correlated with patient clinical data including time of survival.
The initial analysis revealed that each tumor had at least one driver mutation and on
average only 13 genetic mutations, typically five of the 13 were recurrently mutated across
other AML samples. This represents a much lower mutation rate than many other adult
cancers indicating the potency and necessity of these disease-initiating mutations. While
the TCGA dataset provides useful correlative information, its relatively small sample size
limits the ability to determine statistical significance.
TARGET initiative
The Therapeutically Applicable Research to Generate Effective Treatments
(TARGET) initiative represents the most recently curated samples collected from pediatric
patients enrolled in AML trials.269 This project was a collaboration between the Children’s
Oncology Group and the National Cancer Institute with a goal of characterizing AML at
the mutational, transcriptomal, and epigenetic levels. Test results and clinical outcomes
from 993 of the enrolled patients are available, though only 815 were tested for somatic
mutations at the time of diagnosis. A subset (197 samples, 153 of which were paired with
normal tissue) were analyzed by WGS for identification of important mutations and the
remainder by targeted sequencing based on the WGS analysis to enhance read depth. In
addition to DNA sequencing, samples were subjected to DNA methylation profiling and
RNA/microRNA sequencing. As this dataset is restricted to pediatric patients, researchers
were able to identify mutations and chromosomal variations specific to or disproportionate
in young individuals compared to adults with AML. This provides a tool for identification of

81
genetic alterations more relevant to childhood AML and provides a means of comparing
pediatric and adult AML.
These three main datasets encompass the majority of the AML sequencing
information available and for years have provided the means of identifying genetic,
epigenetic, and transcriptomic alterations with potential AML-initiating or promoting
functions. Over the past few decades, cancer research has largely shifted focus from
development of chemotherapeutic drugs to targeted therapies that more precisely attack
genetic changes or cellular alterations specific to tumor cells. The research that led to the
development of many of these new drugs has been guided by information garnered from
datasets such as those listed above. In AML these drugs have proven effective in the
treatment of specific subsets, such as patients with FLT3-ITD, IDH1 or IDH2 mutations, or
BCL2 activation. Despite these new therapies, most AML patients are treated with the
traditional regimen or a less intense derivative thereof.
AML Treatment
Standard treatment
The standard treatment for AML involves an intense regimen of induction
chemotherapy with the addition of an allogeneic stem cell transplant if a suitable donor is
available. Originally developed in 1973, this regimen is often referred to as the standard 7
+ 3 combination: seven days of continuous infusions of cytarabine, also known as cytosine
arabinoside (Ara-C), and three consecutive overlapping days with daunorubicin (DNR)
treatment.270 The compound Ara-C is a combination of cytosine and the sugar arabinose.
It is similar enough in structure to cytosine that it is incorporated into DNA during synthesis
but is different enough that inclusion results in cell death by inhibiting DNA and RNA
synthesis. Ara-C is typically given at a daily dose of 100 – 200 mg/m2, though occasionally
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high-dose treatment of up to 3000 mg/m2 can be administered.271 DNR belongs to the drug
class isolated from the bacterium Streptomyces peucetius known as anthracyclines.
These compounds are extremely effective anti-tumor agents and are used in the treatment
of many different cancers. DNR functions by intercalating into DNA thus inhibiting
topoisomerase activity and preventing separation of the DNA strands and subsequent
synthesis. It is typically given at a dose of 60 mg/m2 per day and can be reduced or even
increased up to 90 mg/m2 if the patient has need of and can tolerate a higher dose.271
Traditional AML treatment comes at a high cost to the patient, particularly because
it attacks the BM resulting in a decrease in blood counts following treatment. This leaves
patients weak and tired due to anemia, easily bruised due to thrombocytopenia, and
susceptible to infection from lack of immune cells, particularly neutropenia. Additionally,
Ara-C and DNR can cause hair loss, nausea and vomiting, and bowel changes, among
other common chemotherapy-related side effects. As the median age at diagnosis is 65,
most of the patients are elderly and cannot withstand the toll this treatment takes on their
bodies. Alternative therapies are limited and patients not infrequently receive palliative
care in lieu of treatment. Even for patients that receive this aggressive treatment, AML has
a high rate of recurrence. Recent FDA approvals have provided four options for the
treatment of relapse and refractory disease: enasidenib, gemtuzumab ozogamicin,
ivosidenib, and gilteritinib (see below). For patients unable to receive one of those
approved treatments, the remaining option is to enter into a clinical trial, should they meet
the eligibility criteria, or receive palliative care.
Recently approved therapies
In the 45 years since its conception, the 7 + 3 treatment regimen has seen very
little change, most notably with the addition of stem cell transplantation in the late 1970s.
Only recently have any drugs been approved by the FDA for the treatment of AML but
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each is limited to a specific subtype of AML and only increase the treatment options for
certain subsets of patients. From 2017 to 2019 the FDA approved seven new drugs:
midostaurin, CPX-351, enasidenib, gemtuzumab ozogamicin, gilteritinib, ivosidenib, and
glasdegib or venetoclax in combination therapies. Midostaurin (PKC412) was originally
developed as an inhibitor of protein kinase C for use in solid tumors but it has since been
found to improve the overall survival of AML patients with FLT3 mutations when added to
standard chemotherapy.272 Gilteritnib (ASP2215, xospata) was also approved specifically
for the treatment of patients with FLT3 mutations but is currently used only as a second
line therapy.273 Enasidenib (AG-221/CC-90007, idhifa) is a first-in-class mutant IDH2
inhibitor that instigates myeloid differentiation, relieving the block in maturation, and is
being used to treat patients with IDH2 mutations for whom prior therapies failed.274
Ivosidenib (AG-120, tibsovo), another first-in-class drug, is the most recently approved
therapy and is an IDH1 mutant inhibitor approved for use in relapse and refractory AML.275
Gemtuzumab ozogamicin (mylotarg) is an anti-CD33 monoclonal antibody conjugated to
a derivative of the anti-tumor antibiotic calicheamicin. Delivery of this drug targets the
leukemic cells and disrupts the DNA, resulting in apoptosis.276 Though initial approval of
gemtuzumab ozogamicin was withdrawn in 2010, new data led the FDA to approve a
different dosing regimen in 2017 for use in relapse and refractory patients. 277 Both
glasdegib and venetoclax were recently approved for use as combination therapies in
patients ineligible for standard induction therapy and have shown greater efficacy than
current therapies for those patients, especially considering it is a population with a high
mortality rate.278 Lastly, CPX-351 (vyxeos) is composed of a combined dose of Ara-C and
DNR encased in a liposome membrane in order to maintain the ideal synergistic molar
ratio of 5:1.279 It is the first therapy approved specifically for patients with t-AML and AML
with myelodysplasia-related changes and can be used as a single agent in lieu of the
standard 7 + 3.280

84
Patients who are relatively healthy and fit are capable of withstanding the harsh
induction chemotherapy treatment and have a fairly good chance of survival. Most of the
patients, however, are elderly with several comorbidities and typically cannot withstand
the aggressive 7 + 3 regimen and alternative treatments lack the toxicity needed to
successfully fight the disease. As a result, less than 15% of patients over the age of 60
achieve complete remission.9 Though younger patients have a higher rate of remission,
AML remains one of the most aggressive hematologic malignancies. The recent advances
in AML therapies illustrate the need for personalized treatment regimens that account for
individual genetic abnormalities and mutations unique to each patient. The
aforementioned therapies provide additional options for patients with FLT3, IDH1, and
IDH2 mutations or who are CD33+ but these therapies are incapable of treating patients
who do not fit into one of those four groups. To enable personalized treatment of AML and
to develop more effective and less toxic therapies suitable for use in additional subtypes,
we must enhance our understanding of the mechanisms underlying AML development
and progression.
AML is characterized by recurrent genetic abnormalities, as described above,
though many of these fusion proteins cannot be directly targeted for treatment. One
mechanism not extensively investigated for development of AML therapies is the UPS and
its individual components. By studying the dysregulation of this system in AML, we will
gain a deeper understanding of leukemia initiation and examine avenues for research and
drug development not limited to a single AML subtype that potentially have implications in
a variety of malignancies. In particular, we will explore the potential therapeutic
implications of altered expression of the SCF E3 ligase FBXO9. Throughout the remainder
of this chapter, we will show that FBXO9 is differentially expressed in patients with AML
and that patients with low expression tend to have a worse prognosis. This led us to
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hypothesize that the dysregulation of FBXO9 within the hematopoietic system alters the
initiation and/or progression of AML. Utilizing our mouse model of AML with the inducible
cKO of Fbxo9, we show that loss of this E3 ligase enhances AML initiation and produces
a more aggressive disease. Through analysis of alterations in the proteomic landscape of
tumors with reduced Fbxo9, we identify proteins and enhanced pathways associated with
tumorigenicity that provide potential targets for patient-dictated therapy regimens.
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Chapter 3 Results
FBXO9 has low expression in AML and expression correlates with poor survival
Of particular interest to us is the SCF family of RING E3 ligases. Not only is this
the largest family of E3 ligases, but many of the individual components have been shown
to regulate pathways highly involved in cancer biology (Figure 1).96 To identify F-box family
members involved in initiation and/or progression of AML, we analyzed patient data from
the MILE study for expression of 61 F-box proteins.267 The MILE study included microarray
expression analyses of specimens from 898 patients, including 28 inv(16), 38 MLLrearranged (MLL), 40 t(8;21), 37 t(15;17), 48 complex karyotype, and 351 normal
karyotype AML patients. Analysis revealed that FBXO9 has the lowest expression in
inv(16), MLL-rearranged (MLL), and t(8;21) leukemias among the F-box proteins.
Additionally, when compared to healthy BM (HBM), CML, and MDS, FBXO9 showed
decreased expression (Figure 14A-B). Further analysis across a wider variety of AML
subtypes, including normal and complex karyotype and t(15;17), revealed that FBXO9 is
consistently downregulated across all subtypes (Figure 14C). In particular, patients with
inv(16) AML had significantly reduced expression when compared to the other subtypes
(normal, p = 0.0002; complex, p < 0.0001; t(15;17), p = 0.0004; t(8;21), p = 0.0086; MLL,
p = 0.0036). These findings are particularly intriguing because of the consistent
downregulation in AML but not in other myeloid malignancies like CML and MDS, the
myeloproliferative disease that often gives rise to AML. This indicates that decreased
FBXO9 expression is specific to AML, independent of the recurrent genetic abnormalities,
and that alteration of its expression is not due to a characteristic associated with a specific
subtype. As AML is the second most common childhood leukemia, we utilized the
TARGET pediatric study of 237 pediatric AML patients to analyze FBXO9 expression and
again found downregulation of FBXO9 in all AML subtypes though not statistically
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significant in pediatric patients with normal karyotype (Figure 14D).281 FBXO9 expression
in inv(16) AML within the pediatric patients is not significantly different from the other
subtypes, with the exception of those with normal karyotype (p = 0.0006) and those
characterized as unknown (p = 0.0118).
Correlation of expression versus survival revealed that adult patients with FBXO9
expression below the median (lower 50% of patients) tend to have a worse prognosis and
shorter time of survival compared to patients with expression above the median (top 50%
of patients), particularly within the first 1500 days post-diagnosis (Figure 15A).268 While
survival differences in the smaller cohort of adult patients only approaches significance,
the larger cohort of pediatric patients demonstrates that within the first 2000 days post
diagnosis, low FBXO9 expression correlated with poor survival (Figure 15B). Patients who
went into remission and survived over 1500 (adult) or 2000 (pediatric) days post initial
diagnosis showed no significant correlation between FBXO9 expression and survival, nor
was the difference significant in any one subtype though those with low FBXO9 trended
toward poor prognosis (Figure 15C-J).268 Taken together, these findings suggest that
FBXO9 expression is decreased in AML tumor cells and that low expression correlates
with poor survival at early times after initial diagnosis.
Deletion of Fbxo9 leads to an aggressive and immature AML phenotype
Considering that FBXO9 expression is reduced in AML patients and that this
reduction correlates with a negative prognosis, we utilized the cKO mouse model
previously described to study the role of FBXO9 in the development and progression of
AML. The lowest expression of FBXO9 was found in the inv(16) subtype of AML. To study
the role of Fbxo9 in inv(16) AML, we crossed our MxCreFbxo9f/f mouse with a mouse
containing the floxed allele of Cbfb-MYH11 (Cbfb+/56M) which allows for inducible
expression of CBFβ-SMMHC following administration of Poly(I:C).261 This mouse contains
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a Lox-stop-Lox cassette in which the penultimate and terminal exons of Cbfb (exons 5 and
6) followed by a stop codon are flanked by LoxP sites. Downstream from this cassette and
the second LoxP site, the genome contains exon 5 fused to the MYH11 gene. Upon
expression of cre, the wildtype exons and stop codon are removed from the genome,
resulting in the formation of the Cbfb-MYH11 fusion gene that codes for the CBFβSMMHC oncogenic fusion protein. In mice, expression of the Cbfb+/56M allele is sufficient
to initiate AML development with a median survival of approximately 20 weeks.261 PCR
analysis confirmed the presence of Cbfb56M and floxed Fbxo9 within the offspring prior to
Poly(I:C) treatment and confirmed deletion of Fbxo9 exon 4 and expression of CbfbMYH11 following Poly(I:C) (Figure 6C).
To monitor disease onset, we performed flow cytometry on PB beginning three
weeks post-Poly(I:C) injection. Cell surface markers for mature myeloid cells, Gr1 and
CD11b, were analyzed along with cKit to identify immature AML blasts. Analysis revealed
that Cbfb+/56MFbxo9+/+ mice tend to have early (two to three weeks) expression of cKit+
cells that diminishes at weeks six and nine. Although not significantly different, the kinetics
of the cKit+ tumor population following Fbxo9 deletion differ and this population expands
at weeks six and nine (Figure 16A). Upon signs of terminal illness, including white toes,
hunched posture, sluggish movement, and palpable spleen, mice were sacrificed and
analyzed for disease state. We found that most of the mice developed AML within the
expected latency period, though the Cbfb+/56MFbxo9+/- group had a significantly shorter
time of survival with a median survival of 14 weeks (p = 0.0037) compared to 17 weeks
in Cbfb+/56MFbxo9-/- (p = 0.0731) and 20 weeks in Cbfb+/56MFbxo9+/+ cohorts (Figure 16B).
Although the Cbfb+/56MFbxo9-/- cohort did not show significance, a larger cohort may reveal
an acceleration of disease initiation.
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Consistent with previously reported data, ~ 80% of mice in the Cbfb+/56MFbxo9+/+
control group had tumors with a predominantly blast-like population, expressing the cell
surface marker cKit, and ~ 20% expressed the more mature cell surface markers Gr1 and
CD11b.261 Upon deletion of Fbxo9, all of the mice from both Cbfb+/56MFbxo9-/- and
Cbfb+/56MFbxo9+/- cohorts developed blast-like tumors expressing cKit on the cell surface
and lacking Gr1/CD11b expression, suggesting a more immature phenotype (Figure 16CE). Consequently, cKO mice had greater expression of cKit in the BM upon sacrifice,
indicating a greater tumor burden in the BM upon loss of one or both Fbxo9 alleles (Figure
16C). These data showed that Cbfb+/56MFbxo9+/- results in a shorter time of survival and
both Cbfb+/56MFbxo9+/- and Cbfb+/56MFbxo9-/- give rise to tumors with a more immature
phenotype.
In addition, we analyzed secondary hematopoietic organs for signs of infiltration.
The spleens from all groups had splenomegaly with the cKO mice trending toward a larger
spleen size (Figure 17A). H & E staining of spleen infiltration demonstrated that ~ 60% of
Cbfb+/56MFbxo9-/- mice had complete effacement of the spleen architecture compared to
only 30% of Cbfb+/56MFbxo9+/+ mice (Figure 5B-C). Likewise, in the liver Cbfb+/56MFbxo9-/mice had ~ 50% infiltration in half the cohort indicating a more aggressive disease even
though they had a similar time of survival to Cbfb+/56MFbxo9+/+ mice (Figure 17D). These
findings suggest that loss of Fbxo9 leads to increased infiltration of tumor cells into the
spleen and liver (n = 7).
Transplanted tumors with reduced Fbxo9 led to rapid onset of disease
Development of primary AML tumors demonstrated that loss of Fbxo9 alters the
initiation and phenotype of inv(16) AML. To determine whether Fbxo9 is acting only in a
tumor initiating fashion or if it also has a role in tumor maintenance, we carried out a
secondary transplantation experiment. Tumor cells from spleens were injected into sub-
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lethally irradiated recipient mice. To eliminate bias from tumor phenotype, we selected
primary splenic tumor cells with a cKit+ phenotype (Figure 18A). All tumors selected
contained > 95% tumor burden with the exception of one Cbfb+/56MFbxo9+/+ tumor with only
80% cKit+ spleen cells. This tumor was selected due to its aggressive nature that resulted
in the shortest survival from the Cbfb+/56MFbxo9+/+ cohort.
We followed the development of AML and by five weeks post-transplant
Cbfb+/56MFbxo9-/- mice had on average 69.6% tumor in the PB compared to only 32.1% in
the Cbfb+/56MFbxo9+/+, indicating that tumors with decreased Fbxo9 develop more rapidly
(Figure 18B). We also observed an earlier effect on normal hematopoiesis, as is seen in
a significant decrease of B220+ cells in the PB of the Cbfb+/56MFbxo9+/- and Cbfb+/56MFbxo9/-

mice at only three weeks post-transplant (Figure 18C). The swift expansion of the tumor

population and rapid impairment of normal hematopoiesis led to decreased time of survival
in

Cbfb+/56MFbxo9+/-

and

Cbfb+/56MFbxo9-/-

transplant

cohorts

compared

to

Cbfb+/56MFbxo9+/+ (Figure 18D). Once again, mice were sacrificed upon signs of terminal
illness in accordance with IACUC standards. Upon sacrifice, analysis of the BM, spleen,
and PB by flow cytometry showed no difference in tumor burden between the three cohorts
(Figure 18E). Staining of fixed tissues with H & E showed infiltration in the spleen and liver
in all three cohorts with many of the spleens showing complete effacement and loss of
normal splenic architecture. Though no difference was observed in spleen infiltration, the
infiltration in the livers of the transplant mice was higher in the Cbfb+/56MFbxo9+/+ cohort
than in either of the cKO cohorts. Contrary to observations in the primary tumors, the
secondary transplants with reduced Fbxo9 gave rise to tumors with less infiltration in the
liver compared to the transplants with WT Fbxo9. The reversal of infiltration likely stems
from the length of survival time. The more aggressive cKO tumors caused such a rapid
progression of the disease in the BM and spleen that they did not have sufficient time to
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infiltrate the liver to the degree of the Cbfb+/56MFbxo9+/+ tumors that developed more slowly
(Figure 18F-G). Secondary transplantation confirms that tumors lacking Fbxo9 are
aggressive and that this protein is involved in maintenance and progression of inv(16)
AML.
Loss of Fbxo9 leads to upregulation of proteins associated with tumorigenicity
To identify potential Fbxo9 substrates and protein alterations in AML, we
performed quantitative MS on splenic tumor cells. Tumor cells were isolated from the
spleens of terminally ill Cbfb+/56M mice with and without homozygous or heterozygous
Fbxo9 cKO. Cells were lysed and the debris pelleted to retrieve the proteins. After cleaning
and quantifying, we labeled the isolated proteins with TMT labels, combined equal
concentrations from each sample, and analyzed by MS (LC-MS/MS; Figure 19A). Mass
spectrometry identified 18696 unique peptides representing 3580 proteins, 3247 of which
were quantifiable (Figure 19B). To quantify protein changes, we compared only proteins
with at least three unique peptides. Between Cbfb+/56MFbxo9+/- and Cbfb+/56MFbxo9-/cohorts, 118 proteins were significantly upregulated (p < 0.05, fold change ≥ 1.3) and 86
proteins were significantly downregulated (p < 0.05, fold change ≤ 0.7) in one or both
cohorts (Figure 19C, see also ProteomeXchange identifier PXD014387).282
The majority of these differentially expressed proteins localized to the cytoplasm
where FBXO9 is expressed (Figure 19D) To determine whether tumors with different
genotypes show distinct patterns of expression, we carried out a principle component
analysis (PCA) and hierarchical clustering and found that three independent tumors with
WT expression of Fbxo9 clustered together while heterozygous and homozygous cKO
tumors clustered together, indicating they are more similar to each other than to their
Cbfb+/56MFbxo9+/+ counterparts (Figure 19E-F). Interestingly, a number of the top
upregulated proteins identified (SERPINB1, ADK, ARF1, UAP1L1, CAPG, FMNL1,
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PAPSS2, USP5, AND GOLPH3) have been shown to participate in cancer by increasing
cell growth and metastasis or are biomarkers for poor outcome (Figure 19F).283-291
Loss of Fbxo9 correlates with increased proteasome activity
The proteins overexpressed upon loss of Fbxo9 were also enriched for proteins
associated with proteasome-mediated pathways such as proteolysis and ubiquitin- or
proteasome-dependent catabolism (Figure 20A). Increased proteasome activity has
previously been implicated in cancer aggressiveness and, accordingly, proteasome
inhibitors have been approved as a treatment.292 Considering this strong correlation
between cancer and proteasome activity, we confirmed proteasome component
overexpression by Western blot analysis and observed an increase in differentially
expressed proteasome components in tumors lacking Fbxo9, though some variation was
seen between the different tumor samples (Figure 20B-C).
Of the differentially expressed proteins, we identified PSMA2, PSMB7, and
PSMD11, three components of the 26S proteasome. The 26S proteasome is composed
of two sub-complexes: the 20S core particle (the catalytic subunit) and the 19S regulatory
particle also known as the cap or the lid.293 The PSMA and PSMB components form a
cylinder of stacked rings with catalytic protease activity sequestered in its core.294 The
PSMC and PSMD components form caps on either end of the cylinder that permit or
prevent substrate engagement with the proteasome.295 Together these two protein subcomplexes form the 26S proteasome that is responsible for the majority of protein
degradation within the cell. The proteasome recognizes proteins tagged with a covalently
linked poly-ubiquitin chain and breaks them down into short peptides that are further
degraded into individual amino acid components. Not only does the proteasome regulate
cellular homeostasis through a variety of processes but it also recycles amino acids
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Though not associated with the proteasome or directly with proteasome-mediated
pathways, ARF1 and SKAP2 were also found to have increased expression upon cKO of
Fbxo9. Src kinase-associated phosphoprotein 2 (SKAP2) is a cytosolic adapter protein
that links integrins to actin filaments. It has been shown to assist in neutrophil migration,
regulate asymmetric cell division of mouse oocytes, and promote tumor-associated M2
macrophage podosome formation that supports invasion and metastasis.296-298 ADPribosylation factor 1 (ARF1) is a small GTPase that regulates vesicle trafficking and is
essential for normal Golgi function.299 It is important for neutrophil cell motility and
chemotaxis and has been shown to play an inhibitory role in allergic inflammation.300,301 In
cancer, ARF1 is capable of MAPK pathway activation that promotes cell growth in prostate
cancer and enables proliferation and migration in breast cancer through PI3K pathway
activation.302 Both ARF1 and SKAP2 have been shown to regulate certain hematopoietic
cells and their expression in tumors promotes cell growth and metastasis. This data
suggests a possible mechanism through which Fbxo9 cKO promotes tumor cell
progression. To determine whether the aforementioned proteins correlate with FBXO9
expression at the RNA level, we analyzed patient data from the MILE study.
Patient tumor RNA expression data revealed no correlation of FBXO9 with ARF1,
PSMA2, PSMB7, and PSMD11 and only a marginal positive correlation with SKAP2
(Figure 21A-E). If RNA expression regulation is occurring in parallel with FBXO9, we would
have expected to see a negative correlation with FBXO9. The lack of correlation suggests
that FBXO9 expression could drive the increase in ARF1, SKAP2, PSMA2, PSMB7, or
PSMD11 protein expression, though further analysis would be needed to prove the
veracity of this supposition. Furthermore, when broken down into AML subtypes, we
observed no significant increase of RNA as would be expected if regulation of these
proteins is occurring during transcription (Figure 21F-J). These findings suggest that RNA
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expression of FBXO9 does not correlate with RNA expression of ARF1, PSMA2, PSMB7,
and PSMD11 and these genes are not differentially expressed at the RNA level in AML.
The lack of significant correlation at the RNA level, however, has no implications on
differential regulation of the proteins. The high protein expression in tumors lacking Fbxo9
suggests that elevated ARF1, SKAP2, PSMA2, PSMB7, or PSMD11 could lead to the
aggressive AML phenotype in mice.
To validate that proteasome component expression correlated with increased
activity in vitro, we performed a proteasome activity assay comparing our three tumor
groups. This confirmed that not only did loss of Fbxo9 result in increased proteasome
component expression but that this expression correlated with increased proteasome
activity in the Cbfb+/56MFbxo9+/- and Cbfb+/56MFbxo9-/- tumors (Figure 22A). To further
elucidate the effect of loss of Fbxo9 in AML, we treated cultured tumor cells with varying
concentrations of the proteasome inhibitor bortezomib (Figure 22B). Cells treated for 24
hours with bortezomib confirmed that Cbfb+/56MFbxo9-/- tumor cells were more sensitive to
proteasome inhibition than Cbfb+/56MFbxo9+/+ tumor cells with IC50 calculations of 10.03 nM
and 11.76 nM, respectively. Analysis of cell death by flow cytometry after 16 hours
bortezomib treatment demonstrated that Cbfb+/56MFbxo9-/- tumor cells trended toward
increased sensitivity compared to Cbfb+/56MFbxo9+/+ tumor cells (Figure 22C). A longer
treatment time is required to achieve statistical significance. These studies provide
evidence that loss of Fbxo9 leads to increased proteasome activity and sensitivity to
proteasome inhibitors like bortezomib.
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Chapter 3 Conclusion
The molecular pathogenesis of AML has yet to be fully defined, though many
acquired molecular and cytogenetic abnormalities have been identified that lead to
leukemogenesis.303 Aberrant FBXO9 expression has previously been linked to disease
progression in MM by regulation of mTORC1 components and tagging them for
degradation159. In this context, its overexpression was shown to promote disease
progression and thus FBXO9 has previously been classified as an oncogene. Contrary to
its role in MM, our studies demonstrate that FBXO9 expression is consistently decreased
across AML subtypes. The reduction of its E3 ligase activity promotes the progression of
AML and tends to decrease survival time both in mouse studies and patient cohorts. MS
experiments did not show accumulation of the known substrates TEL2 and TTI1 identified
in MM indicating that FBXO9 has an alternative mechanism of action in leukemia. This
finding demonstrates that FBXO9 plays a context-specific role in cancer, acting as an
oncogene in MM and a tumor suppressor in AML. While many other F-box proteins have
been shown to have solely oncogenic or tumor suppressor roles, FBXO9 is among a few
select members of the family that can function in both capacities.91 Furthermore, we found
that loss of a single copy of Fbxo9 was sufficient to cause increased aggressiveness in
AML tumor cells. Considering that FBXO9 is an E3 ligase, it was important to identify the
alterations that loss of this protein causes in the proteomic landscape of AML cells.
Through interrogation of the proteomic changes occurring in murine AML tumor
cells upon loss of Fbxo9, we identified various proteasome components and proteasomerelated proteins that were upregulated. Increased proteasome activity has been
associated with aggressiveness in many cancer types through in vitro and in vivo
studies.304-307 Ma et al. reported that AML patients had higher levels of 20S proteasome
components compared to healthy controls but that this increase did not lead to increased
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chymotrypsin-like activity due to a reduction in expression of the 19S regulatory
component.308 Similarly, our data showed increased expression of the 20S catalytic
subunit

components

(PSMA

and

PSMB)

in

Cbfb+/56MFbxo9-/-

compared

to

Cbfb+/56MFbxo9+/+. Unlike the results produced by Ma et al., we saw increased expression
in the 19S (PSMD) components indicating that loss of Fbxo9 could correspond with altered
proteasome activity. Further analysis revealed that increased component expression was
associated with increased proteasome activity, suggesting a direct link between the two
alterations.
Proteasome inhibition with drugs such as bortezomib has become standard of care
for patients with MM and has been effectively utilized as a second-line therapy in treating
mantle cell lymphoma and follicular lymphoma.309-311 Clinical trials using bortezomib to
treat AML, either alone or as a combination drug, have reported varying complete
remission rates ranging from 0-80%.312-318 To date, no specific AML mutation or
classification has been correlated with patient response to proteasome inhibition. Indeed,
responses seem to be independent of AML subtype. Furthermore, one of the main
impediments to achieving complete remission in AML stems from the inability of current
therapies to target the leukemic stem cells. Bortezomib has the additional benefit of being
more effective in targeting leukemic stem cells, cells that rely heavily upon proteasome
activity for survival.319,320
Proteasome inhibitors have previously been effective in targeting the tumorinitiating population and mature tumor cells and the findings presented herein could lead
to more efficacious clinical use of agents like bortezomib. In general, bortezomib is welltolerated and has minimal side effects in adults with the exception of patients
hypersensitive to bortezomib, boron, or mannitol.321 The Children’s Oncology Group
conducted a randomized trial in 1097 pediatric patients with AML in which they treated
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with standard chemotherapy with or without the addition of bortezomib.322 They found that
bortezomib did not improve overall event free survival in children but had increased
peripheral neuropathy, contraindicating the addition of bortezomib to the treatment
regimen of pediatric patients with de novo AML.322 Therapeutic use of bortezomib to treat
AML may not be suitable for all adult patients but in those for whom first-line therapies
prove ineffective, bortezomib could provide the treatment needed to improve patient
outcome particularly with improved methods of predicting patient response. Overall, we
have identified Fbxo9 as a tumor suppressor of AML and shown that loss of its expression
leads to increased proteasome activity and sensitivity to proteasome inhibition, thus
implying that FBXO9 expression could be used as a biomarker to identify patients who
would respond well to proteasome inhibition.
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Figure 13
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Figure 13 AML is the most common and deadly hematologic malignancy. A Bar
graph of predicted incidence and leukemia-related deaths for 2019. B Pie charts of the
common AML subtypes for adult and pediatric patients.
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Figure 14
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Figure 14 FBXO9 has reduced expression in AML patients. A and B Heatmap of
relative RNA expression of F-box proteins in A adult and B pediatric patients (* denotes
FBXO9). C and D Patient RNA expression in C adult and D pediatric patients across all
analyzed subtypes compared to healthy BM – number of patients per subtype in
parentheses (* p < 0.05, ** p < 0.01, **** p < 0.0001).
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Figure 15
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Figure 15 FBXO9 expression in patients correlates with a shorter time of survival in
the initial period following diagnosis. A Survival of adult patients in first 1500 days postdiagnosis. B Survival of pediatric patients in first 2000 days post-diagnosis. C Survival of
adult patients up to 3000 post-diagnosis. D Survival of pediatric patients up to 4000 days
post-diagnosis. E-J Survival of pediatric patients of various subtypes (for all graphs,
patients grouped by FBXO9 expression above (high, green) or below (low, red) the
median.
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Figure 16
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Figure 16 Loss of Fbxo9 accelerates inv(16) AML progression and results in a more
immature tumor phenotype. A Analysis of the PB of mice following initiation of inv(16)
AML. B Kaplan-Meier survival curves of Poly(I:C) treated mice (n = 8). C and D Bar graphs
representing percentage of C cKit+ tumor cells or D Gr1+/CD11b+ cell in the BM of mice at
time of sacrifice. E Representative FACS plots of tumor cells isolated from the BM of mice
at time of sacrifice, gated on live singlets (all bar graphs mean ± standard deviation, ns =
not statistically significant, * p < 0.05, ** p < 0.01).
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Figure 17
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Figure 17 Fbxo9 cKO results in a more aggressive AML phenotype. A Bar graph of
spleen weight of mice at time of sacrifice. B Representative images of Wright-Giemsastained PB and hematoxylin-eosin (H&E)-stained spleen and liver sections of mice with
the indicated genotypes at time of sacrifice. Bars, 20 µm. C and D Quantification of the
infiltration in the C spleen (Cbfb+/56MFbxo9+/−, p = 0.6751 and Cbfb+/56MFbxo9−/−, p =
0.7647) and (G) liver (Cbfb+/56MFbxo9+/−, p > 0.9999 and Cbfb+/56MFbxo9−/−, p = 0.4128),
where 100% represents infiltration and complete effacement while 0% represents no
infiltration with normal tissue architecture (n = 7).
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Figure 18
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Figure 18 Transplant of inv(16) spleen tumor cells with lower expression of Fbxo9
develop more aggressively. A FACS plots of spleen tumor cells transplanted into sublethally irradiated host mice. B Bar graph representing the percentage of cKit+ cells in the
PB of transplant mice. C Overall survival of mice transplanted with tumors of the indicated
genotypes. D Bar graph of B cell (B220) expression in the PB following transplantation. E
Bar graph of percentages of cKit+ tumor cells in the BM, spleen (SP), and PB at time of
sacrifice. F and G Bar graphs of F spleen (Cbfb+/56MFbxo9+/−, p = 0.0890 and
Cbfb+/56MFbxo9−/−, p = 0.1356) and G liver infiltrations where each datapoint represents an
individual mouse (all graphs are mean ± standard deviation; n = 10; * p < 0.05, ** p < 0.01,
*** p < 0.001, **** p < 0.0001).
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Figure 19

A

Cbfb+/56MFbxo9+/+

Isolate

Prep

Label

Mix

Fractionate,
LC-MS/MS

Cbfb+/56MFbxo9+/-

Cbfb+/56MFbxo9-/-

B

F

Peptides: 18696

min

max

Proteins: 3580
Cbfb+/56MFbxo9-/Cbfb+/56MFbxo9-/Cbfb+/56MFbxo9-/Cbfb+/56MFbxo9+/Cbfb+/56MFbxo9+/Cbfb+/56MFbxo9+/+
Cbfb+/56MFbxo9+/+
Cbfb+/56MFbxo9+/+

Quantified: 3247
≥3 Peptides: 1970
Differentially
Expressed: 204

C

No effect

1×10 -4

p-value

1×10 -3
0.01
p = 0.05

0.1
1.0
0.25

0.5

0.7

1

1.3

2

4

Effect size (ratio)

D

4 4
13

77

106

Cytoplam
Nucleus
Plasma Membrane
Extracellular Space
Other/Unspecified

E
Cbfb+/56MFbxo9+/+

Cbfb+/56MFbxo9+/Cbfb+/56MFbxo9-/-

Analyze
Quantify

108
Figure 19 Tumors lacking Fbxo9 are more similar than tumors with WT expression.
A Schematic of preparation for TMT-MS using tumors isolated from Cbfb+/56MFbxo9+/+,
Cbfb+/56MFbxo9+/−, and Cbfb+/56MFbxo9−/− mice (n = 3). B Quantification of the identified
peptides and proteins. C Volcano plot of the fold change Cbfb+/56MFbxo9−/−/
Cbfb+/56MFbxo9+/+ samples for significantly upregulated and significantly downregulated
proteins (pink, significantly upregulated in Cbfb+/56MFbxo9+/−/Cbfb+/56MFbxo9+/+; yellow,
proteins participating in proteasome-dependent pathways; green, top upregulated
proteins associated with tumorigenicity). D Pie chart of localizations for the differentially
expressed proteins identified in either the Cbfb+/56MFbxo9+/−, Cbfb+/56MFbxo9−/−, or both
cohorts. E PCA plot using components 1 and 2, showing clustering of Cbfb+/56MFbxo9+/+
tumors compared to Cbfb+/56MFbxo9+/− and Cbfb+/56MFbxo9−/− tumors. F Heatmap with
hierarchical clustering of the significantly upregulated proteins (p < 0.05, ≥ 1.3-fold
increase over WT) and downregulated (p < 0.05, ≤ 0.7-fold decrease from WT).
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Figure 20 Fbxo9 cKO results in an increase in proteasome components and
proteasome-regulated pathways. A Gene ontology analysis showing pathways known
to be associated with proteins significantly upregulated (p < 0.05, ≥ 1.3-fold change), using
DAVID 6.8 software. For upregulated proteins, pathways included have ≥ 10 associated
proteins and p < 0.01. B Western blot analysis of identified upregulated proteins and
proteasome components for expression in murine inv(16) AML tumors with the indicated
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Figure 21
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Figure 21 RNA expression correlation of UPS-associated proteins. A-E FBXO9 has
no correlation with A ARF1, B PSMD11, C PSMA2, or D PSMB7 but has a marginal
positive correlation with E SKAP2 (the r-value was calculated using the Pearson
correlation coefficient where r < 0.3 represents no correlation, 0.3 < r < 0.7 represents
moderate correlation, and r > 0.7 represents strong correlation; the p-value calculated
represents the accuracy of the r-value). F-J Violin plots of RNA expression from the MILE
study for F ARF1, G PSMD11, H PSMA2, I PSMB7, and J SKAP2 (ns = not significant, *
p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001).

112
Figure 22
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Figure 22 Knockout of Fbxo9 results in an increase in proteasome activity and
differing response to proteasome inhibitors in vitro. A Bar graph of proteasome
activity in cultured tumor cells using the indicated amounts of protein, proteasome activity
confirmed by treatment with the proteasome inhibitor lactacystin. B Bar graph showing
survival of Cbfb+/56MFbxo9+/+ and Cbfb+/56MFbxo9−/− tumor cells after 24 hours culture with
increasing doses of bortezomib. C Bar graph quantifying cell death of tumors cultured 16
hours with 20 nM bortezomib, cell death analyzed by flow cytometry using Annexin-V and
7AAD; for live/dead, p = 0.1502 (for all data shown n = 3, all bar graphs are mean ±
standard deviation, ns = not statistically significant * p < 0.05, ** p < 0.01).
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CHAPTER 4:
SUMMARY AND FUTURE DIRECTIONS
Summary
The primary focus of this work is on the molecular regulation of normal and
malignant hematopoiesis by the E3 ubiquitin ligase FBXO9. FBXO9 belongs to a family of
proteins characterized by their F-box domain that permits their inclusion in the SCF RING
E3 ligase complex as the substrate recognition component. Of the 69 family members,
some have been characterized for their role in hematopoiesis and hematopoietic
malignancy, most notably the protein FBXW7. The role of other family members, including
FBXO9, has not been extensively studied, though they may prove to be integral to
hematopoietic homeostasis. Of the F-box family members, we were initially drawn to
FBXO9 due to its high RNA expression in HSCs and consistent downregulation across all
AML subtypes. The role of this protein has been studied in the context of MM, where its
upregulation was shown to promote tumor progression. This was in direct opposition to
our finding that FBXO9 expression is reduced in AML patients. Due to these observations,
we hypothesized that FBXO9 plays a crucial role in the maintenance of HSCs and that it
acts as a tumor suppressor of AML in the tumor initiating population.
To initiate our studies, we developed a mouse model with a conditional knockout
of Fbxo9 in the hematopoietic system, including in the HSCs. While not a complete
knockout, removal of exon 4 disrupts the TPR protein binding domain and induces a
frameshift leading to loss of the F-box domain and premature truncation. We induced
deletion of Fbxo9 in hematopoietic cells and analyzed the mice for differences in stem cell
proliferation and defects in hematopoiesis. Loss of Fbxo9 did not lead to spontaneous
development of leukemia nor did we see conclusive evidence that loss of FBXO9 impaired
HSCs. Further studies confirmed that mature hematopoietic lineages, B and T lymphoid
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as well as myeloid, remained stable despite loss of this highly expressed protein. The
most striking phenotypic difference was in the cKit+ progenitor cells where loss of Fbxo9
resulted in a small, though significant, decrease in total cell number. Using mass
spectrometry, we identified an array of proteins selectively regulated upon loss of Fbxo9
and under conditions of hematopoietic stress. Many of the proteins up- and downregulated
participate in metabolism, a process tightly regulated in HSPCs and one that is altered
upon malignant transformation.
Next, we extended our studies to include leukemogenesis. The lowest levels of
FBXO9 expression in AML patients were observed in the inv(16) subtype in which
leukemia is driven by the characteristic fusion protein CBFβ-SMMHC. Following Fbxo9
deletion and Cbfb-MYH11 expression in the hematopoietic system, we found that loss of
Fbxo9 contributed to alterations in leukemia initiation, disease progression, and
phenotype of the tumor cells. Decreased levels of Fbxo9 correlated with decreased time
of survival, particularly in the heterozygous knockout. Though the difference in survival
time of the homozygous knockout lacks statistical significance, analysis of primary tumor
cells and secondary organs at time of sacrifice revealed increased tumor infiltration and a
more immature cellular phenotype. Interestingly, transplantation of phenotypically similar
tumor cells from mice with Cbfb+/56MFbxo9+/+, Cbfb+/56MFbxo9+/-, and Cbfb+/56MFbxo9-/- AML
demonstrated that loss of one or both copies of functional FBXO9 gave rise to a more
aggressive tumor as seen in the drastically shorter time of survival.
Analysis of the changes to the proteome following depletion of Fbxo9 revealed that
some of the upregulated proteins are involved in proteasome-mediated pathways,
including a variety of proteasome components. The proteasome has previously been
linked to cancer progression and, in particular, leukemic stem cells have increased
proteasome activity. An in vitro proteasome activity assay confirmed that Fbxo9 knockout
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correlates with increased proteasome activity. The efficacy of the proteasome inhibitor
bortezomib in the treatment of AML has been examined in a series of clinical trials in both
adult and pediatric patients. While associated neurotoxic side effects contraindicate its
use in pediatric patients, it is well tolerated in adults and has been used as both first- and
second-line therapies to treat other hematologic malignancies. To compare the effect of
bortezomib treatment on tumors with varying expression of Fbxo9, we cultured tumor cells
with bortezomib for 24 hours. The cells deficient in Fbxo9 displayed enhanced sensitivity
and increased cell death when exposed to bortezomib, indicating that knockout of Fbxo9
creates a dependency upon proteasome activity for survival. Functional studies will
illustrate whether FBXO9 depletion has the same effect in vivo as we observed in our in
vitro studies. If this is the case, then efforts to determine FBXO9 expression in human
patients would be advantageous for identification of patients that would respond well to
proteasome inhibition should front-line therapies fail to achieve a complete remission.
Future Directions
The findings from the Fbxo9 knockout studies in mice have shown that this protein
plays an important role in AML initiation and progression but leave many questions to be
answered. First and foremost, what is the Fbxo9 substrate whose altered expression
affects HSPCs and leads to leukemogenesis? Following up with that, what is the clinical
relevance of FBXO9 expression and how is it regulated? The following experiments
address the impact of FBXO9 expression on patient outcome but also the upstream
regulators and downstream targets of FBXO9 E3 ligase activity.
Identifying and validating FBXO9 substrate(s) dysregulated in AML
Utilizing the mass spectrometry analyses from the tumor samples, we can identify
potential substrates that are targeted for degradation by FBXO9-mediated ubiquitination.
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Loss of FBXO9 and its E3 ligase activity will cause an accumulation of substrate proteins
in tumors from Cbfb+/56MFbxo9+/- and Cbfb+/56MFbxo9-/- mice. Potential substrates will be
validated by co-overexpressing them along with FBXO9 in 293T cells, followed by coimmunoprecipitation with FBXO9 to determine whether the two proteins interact. This will
allow us to determine protein-protein interaction but does not indicate whether that
interaction is due to a substrate-ligase relationship. Treatment of cell lines with MG132, a
proteasome inhibitor, and monitoring for potential substrate accumulation will identify
those proteins that are degraded by the proteasome. Proteins that are degraded by the
proteasome and are shown to interact with FBXO9 can then be validated as substrates
using co-overexpression with the mutant Fbxo9 plasmids described in chapter two
(Fbxo9ΔF-box, Fbxo9ΔTPR, and Fbxo9ΔExon4) while again treating with MG132. Substrate
proteins co-transfected with the mutant Fbxo9 plasmids will show no additional
accumulation upon treatment with MG132 but those that are not true FBXO9 substrates
will accumulate even when co-expressed with a binding deficient Fbxo9 mutant.
To further narrow the pool of potential substrates, we can cross reference the list
of proteins upregulated in tumors with the list of proteins upregulated in Fbxo9-/- mice
during stress hematopoiesis. Interestingly, both MS analyses revealed increased
expression of proteins involved in metabolic processes. This implies that FBXO9 plays a
role in the regulation of metabolism, a process frequently dysregulated in tumor cells.
While non-transformed cells may be resistant to the metabolic alterations occurring with
loss of Fbxo9, tumor cells may benefit from the changes and thus develop increased
tumorigenicity when levels of Fbxo9 are decreased. Additionally, studies to determine
changes in metabolism within HSCs and AML tumors can provide a greater understanding
of the mechanisms regulated by FBXO9 that promote cancer cell survival.
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Determine the clinical significance of FBXO9 expression on AML
In continuation of the in vitro assays with bortezomib treatment of tumor cells, the
next step is to treat leukemic mice with bortezomib and determine whether or not it elicits
a change in survival of mice with reduced expression of Fbxo9. Poly(I:C)-treated mice
would be monitored for leukemia cell development and upon reaching a threshold of tumor
burden, mice would be treated with bortezomib and monitored for disease progression.
Results of this treatment would indicate the clinical efficacy of therapeutic use of
bortezomib in patients with low expression of FBXO9.
To further verify that expression of Fbxo9 impacts tumor cell initiation and
progression, a doxycycline (dox)-inducible FBXO9 overexpression system will be
developed in patient derived cell lines such as ME-1 (CBFβ-SMMHC), Kasumi-1 (RUNX1ETO), or Molm-13 (MLL-AF9). The cell lines will be transplanted into immunodeficient
NSG mice and either treated with dox immediately after transplant or following
establishment of the tumor within the bloodstream. Treatment with dox following
transplantation will cause an immediate overexpression of FBXO9 that will allow for the
determination of whether high expression is sufficient to delay or prevent onset of disease.
Dox treatment after tumor establishment will show whether or not FBXO9 overexpression
can reduce tumor burden or perhaps halt tumor progression. These studies will provide
evidence that FBXO9 is not simply a biomarker but perhaps a therapeutic target to achieve
more effective AML treatments. While delivery of exogenous FBXO9 itself is likely not an
option for therapy, further understanding of the mechanisms regulating FBXO9 expression
will provide potential therapeutic targets that will increase its expression upon drug
treatment.
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Elucidate the mechanism by which FBXO9 downregulation occurs
Microarray and RNA-Seq data from the MILE and TARGET studies has shown a
consistent downregulation of FBXO9 at the transcriptomic level. I would expect that
regulation of FBXO9 would occur through one of three mechanism: epigenetic variations,
signaling pathway alterations, or transcription factor dysregulation. We know that changes
in the epigenome are common in AML, so to begin we could analyze methylation patterns
in patient samples to identify changes that might inhibit RNA polymerase access to
chromosome 6 where the FBXO9 gene is located. Inappropriate signaling of pathways
such as NOTCH and the mitogen-activated protein kinase (MAPK) cascade are often
associated with leukemic transformation in myeloid cells. Specific inhibitors or stimulators
of these and other pathways in non-transformed cells could identify a signaling cascade
responsible for the downregulation of FBXO9. Finally, an analysis of patient samples for
loss of transcription factors or increase in expression of transcriptional repressors could
indicate a possible mechanism for FBXO9 regulation in AML. Identification of the system
that regulates FBXO9 transcription will provide a better understanding of how the UPS
and its E3 ligases are regulated in malignant hematopoiesis and provide potential
therapeutic targets for AML patients.
These proposed studies will provide valuable insight into the contribution of loss of
FBXO9 in HSCs and in AML initiation and progression. Understanding the role of FBXO9,
its upstream regulators, and its substrates in normal and malignant hematopoiesis will
demonstrate the significance of better understanding the UPS and the clinical efficacy of
targeting FBXO9 in AML patients.
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CHAPTER 5:
MATERIALS AND METHODS
RNA extraction and quantitative RT-PCR
Total RNA was harvested from BM cells using the RNeasy Kit (QIAGEN, Hilden,
Germany). Following extraction, total RNA was used for cDNA synthesis using the High
Capacity RNA-to-cDNA Kit (ThermoFisher). cDNA was quantified by measuring
absorbance at A280 nm and qRT-PCR was carried out on equal concentrations of cDNA
from each sample using the iTaq Universal SYBR Green Supermix (BioRad, Hercules,
CA, USA). Primers are listed in Table 10.
Transgenic mouse models
Fbxo9 cKO mice were developed using Easi-CRISPR as previously published245
and bred with Cbfb+/56M

245,261

or Mxcre mice purchased from Jackson Laboratories

(#003556, Bar Harbor, ME, USA). PCR confirmed genotype and expression (primers in
Table 7). To induce cKO of Fbxo9 and expression of Cbfb-MYH11, 6 – 8-week old floxed
mice and littermate controls received three intraperitoneal Poly(I:C) injections every other
day at a dose of 10 µg per gram body weight (Invivogen). Genotyping PCR was carried
out using the primers listed below. Procedures performed were approved by the
Institutional Animal Care and Use Committee (IACUC) of the University of Nebraska
Medical Center (UNMC) in accordance with NIH guidelines.
Western blot analysis
For Western blot analysis, samples were lysed in an IP lysis buffer (20 mM Tris pH
7.5, 150 mM NaCl, 1 mM EDTA) containing 1X Halt Protease and Phosphatase Inhibitor
Cocktail (ThermoFisher, Waltham, MA, USA) and 10 mM N-ethylmaleimide. Membranes
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were blocked in 5% milk. Antibodies were prepared in 5% BSA. Horseradish peroxidase
conjugated secondary antibodies (Jackson Laboratory) were prepared in 5% milk.
Antibodies are listed in Table 9.
Flow cytometric analysis
For flow cytometric analyses, PB was extracted from the tail vein and RBCs were
lysed with 500 µL ACK lysing buffer. Upon sacrifice, spleen and BM cells were passed
through 0.45 µm strainer and treated with ACK lysing buffer. Spleen, BM, and PB cells
were stained for 1 hour on ice in the dark in 3% FBS in PBS (antibodies are listed in Table
8). For cell cycle analysis, cells were fixed and permeabilized following Biolegend
intracellular staining protocol and stained with anti-Ki67, antibodies to identify LSKs, and
DAPI using 10 µL DAPI per sample. Antibodies are listed in Table 8.
Colony forming cell (CFC) assay
Freshly isolated BM or culture progeny from total BM were counted and 5000
cells/well of a 24-well plate were resuspended in Methocult (M3434, Stem Cell
Technologies, Vancouver, BC, Canada). Colonies were counted at day 7, resuspended,
and replated as before.
Transplantation
One day prior to irradiation, antibiotics were added to the water. Mice were lethally
irradiated with 10 Gy or sub-lethally irradiated with 6 Gy 4 – 12 hours prior to
transplantation. Samples were prepared under sterile conditions and suspended in sterile
PBS. Lethally irradiated mice received at least 1 x 106 BM or helper BM cells from a
healthy, untreated WT syngeneic mouse to provide radioprotection. BM or tumor cells
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were transplanted via tail vein injection and mice were housed and treated according to
approved UNMC IACUC protocols in accordance with NIH guidelines.
5-FU treatment
Following Poly(I:C) treatment and recovery time, mice were weighed and injected
with 150 mg/kg 5-FU either once (for the MS analysis) or on a weekly basis (for the survival
analysis) insofar as they would tolerate the treatment. Mice were monitored for signs of
BM failure including hunched posture, decreased activity, white toes, and loss of appetite.
Upon appearance of these signs, mice were sacrificed immediately.
TMT labeling and mass spectrometry
For global proteome quantification, BM cells (for stress hematopoiesis) or splenic
tumor cells (for AML) were isolated as described above from 2-3 mice per genotype.
Samples were prepared and TMT-labeled per manufacturer’s protocol (ThermoFisher
TMT10plex Mass Tag Labeling Kits). Following TMT labeling, acetonitrile was removed
by speedvac and samples were resuspended in 0.1% trifluoroacetic acid. Sample cleanup
with C18 tips was performed per manufacturer’s protocol (Pierce). Sample concentrations
were re-quantified (Pierce Quantitative Colorimetric Peptide Assay kit) and combined in
equal concentration. Following combination, samples were dried by speedvac and
fractionated using the ThermoFisher high pH reverse phase fractionation kit following the
manufacturer’s protocol for TMT. Resulting fractions were dried in a speedvac and
resuspended in 0.1% Formic Acid for MS analysis. Data from the AML MS analysis are
available via ProteomeXchange with identifier PXD014387.282
Samples were loaded onto trap column Acclaim PepMap 100 75 µm x 2 cm C18
LC Columns (ThermoFisher) at a flow rate of 5 µl/min and then separated with a Thermo
RSLC Ultimate 3000 (ThermoFisher) from 5-20% solvent B (0.1% FA in 80% ACN) from
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10-98 min at 300 nL/min and 50 ºC with a 120 min total run time for fractions one and two.
For fractions three to six, solvent B was used at 5-45% for the same duration. Eluted
peptides were analyzed by a Thermo Orbitrap Fusion Lumos Tribrid (ThermoFisher) mass
spectrometer in a data dependent acquisition mode using the synchronous precursor
selection method. A survey full scan MS (from m/z 375-1500) was acquired in the Orbitrap
with a resolution of 120000. The AGC target for MS2 in iontrap was set as 1 x 104 and ion
filling time set as 150 ms and fragmented using CID fragmentation with 35% normalized
collision energy. The AGC target for MS3 in orbitrap was set as 1 x 105 and ion filling time
set as 200 ms with a scan range of 100-500 and fragmented using HCD with 65%
normalized collision energy. Protein identification was performed using proteome
discoverer software version 2.2 (ThermoFisher) by searching MS/MS data against the
UniProt mouse protein database. The search was set up for full tryptic peptides with a
maximum of 2 missed cleavage sites. Oxidation, TMT6plex of the amino terminus, GG
and GGQ ubiquitination, phosphorylation, and acetylation were included as variable
modifications and carbamidomethylation and TMT6plex of the amino terminus were set
as fixed modifications. The precursor mass tolerance threshold was set at 10 ppm for a
maximum fragment mass error of 0.6 Da with a minimum peptide length of 6 and a
maximum peptide length of 144. The significance threshold of the ion score was calculated
based on a false discovery rate determined using the percolator node. Protein accessions
were

put

into

Ingenuity

Pathway

Analysis

(QIAGEN

Inc.,

https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis) to identify
gene symbols and localizations. Gene ontology pathway analysis was performed using
DAVID Bioinformatics Database 6.8 using the functional annotation tool.
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Patient datasets
FBXO9 expression and survival analyses in adult and pediatric patients are
derived from the Microarray Innovations in Leukemia (MILE) study267, the Therapeutically
Applicable Research to Generate Effective Treatments (TARGET)281, and the Genomic
and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia268. Patient
statistics can be found in Tables 6A-C. Heatmap generation was carried out by calculating
the Z-score for each individual F-box in order to make comparisons between subtypes
and among the different F-boxes. Violin plots were generated by plotting the log2 RNA
expression for each patient within the various subtypes.
Histological staining
Mouse organs were fixed in 10% (vol/vol) buffered formalin phosphate for 24 hours
and stored in 70% ethanol. Sections were stained with H&E using standard protocols. The
slides were evaluated and graded by treatment group by a pathologist for leukemia
infiltration.
Proteasome activity assay
Tumor cells isolated from spleen tissue (2 x 106) were lysed in 0.5% NP-40 in PBS
for 10 min on ice with vortexing. 5-10 µg protein lysates were cultured and proteasome
activity measured using the 20S Proteasome Activity Assay kit (APT280, Millipore,
Billerica, MA, USA) per manufacturer’s protocol.
MTT assay
2 x 105 cells were plated into each well of a 96-well plate and cultured for 24 h in
100 µL tumor growth medium (StemSpan SFEM, 5% Penn/Strep, 5% Lipid mixture, 5%
Glutamate, 20 ng/mL SCF, 10 ng/mL IL-6, 10 ng/mL IL-3) containing DMSO or varying
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concentrations of bortezomib. Following culture, CellTiter 96 AQueous One Solution Cell
Proliferation Assay (MTS) (Promega, Madison, WI, USA) was performed per
manufacturer’s protocol.
Statistical analysis
All experiments were performed in triplicate unless noted and statistical analyses
were performed using unpaired two-tailed Student's t-test assuming experimental samples
of equal variance. ns = not significant, * p-value < 0.05, ** p-value < 0.01, *** p-value <
0.001, **** p-value < 0.0001.
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Table 6A-C AML dataset patient statistics
A
Class
HBM
MDS
Normal
Complex
inv(16)
t(15;17)
t(8;21)
MLL
CML
Total

MILE Study Diagnosis
Non-leukemia and healthy bone marrow
Myelodysplastic syndrome
AML with normal karyotype
AML with complex karyotype
AML with inv(16)/t(16;16)
AML with t(15;17)
AML with t(8;21)
AML with t(11q23)/MLL
Chronic myeloid leukemia

No of Samples
74
206
351
48
28
37
40
38
76
898

Class
HBM
Unknown
Normal
inv(16)
t(8;21)
MLL
Other
Total

TARGET Study Diagnosis
Non-leukemia and healthy bone marrow
AML with unknown diagnosis
AML with normal karyotype
AML with inv(16)/t(16;16)
AML with t(8;21)
AML with t(11q23)/MLL
AML with other diagnoses

No of Samples
5
10
53
36
45
41
47
237

FAB Subtype
AML M0
AML M1
AML M2
AML M3
AML M4
AML M5
AML M6
AML M7
Other
Total

TCGA Study Diagnosis
AML with minimal maturation
AML without maturation
AML with maturation
Acute promyelocytic leukemia
Acute myelomonocytic leukemia
Acute monoblastic or monocytic leukemia
Acute erythroid leukemia
Acute megakaryoblastic leukemia
Other subtypes

No of Samples
15
41
42
15
37
22
2
3
2
179

B

C
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Table 7 Genotyping primers
Genotyping Primer
Fbxo9 5’ F
Fbxo9 5’ R
Fbxo9 3’ F
Fbxo9 3’ R
Hygro F
Hygro R
Generic Cre F
Generic Cre R
Inv Post F
Inv Post R

Sequence
5’ – GTC TCT TCG AGG CAG AAC GTA TC – 3’
5’ – GCA ACG GGA TCA GAT GTC CAA TG – 3’
5’ – GCC TGA GAC TGA AAG ATC CTT GC – 3’
5’ – CAG GCT TAC AAA GAG GGC CTA CG – 3’
5’ – CCA TCG TCG AGA TCC AGA CAT – 3’
5’ – GTA TAT GCT CCG CAT TGG TCT TG – 3’
5’ – GCG GTC TGG CAG TAA AAA CTA TC – 3’
5’ – GTG AAA CAG CAT TGC TGT CAC TT – 3’
5’ – CCC CCG TAC TGT GTG TGT CT – 3’
5’ – GCC AGA CGG GTC AAC AAT AC – 3’
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Table 8 Flow cytometry antibodies
Antibody
7-AAD
Annexin V
B220
CD4
CD8

Fluorochrome
n/a
PE
PacBlue, BV510, APCcy7, APC,
Biotin, PE
APCcy7, APC, Biotin, PE
APCcy7, APC, Biotin, PE

CD11b
CD16/32
CD34
CD48
CD131
CD150
cKit
Gr-1
Ki67
Sca-1

FITC, APCcy7, APC, Biotin, PE
FITC, APC
APC, PE
FITC
PE
BV510, BV785
APC, BV421, PacBlue
APCcy7, APC, Biotin, PE, BV421
FITC
PE, PEcy7

Strep
Ter-119

FITC
APCcy7, PacBlue, APC, Biotin, PE

Clone
n/a
n/a
RA3-6B2
CK1.5
53-6.7

Company
eBioscience
BioLegend
BioLegend

BioLegend
BioLegend,
eBioscience
M1/70
BioLegend
93
BioLegend
HM34
BioLegend
HM48-1
BioLegend
n/a
BD Pharmingen
TC15-12F12.2 BioLegend
2B8
BioLegend
RB6-8C5
BioLegend
16A8
BioLegend
D7
BioLegend,
eBioscience
n/a
BioLegend
TER-119
BioLegend

128
Table 9 Western blot antibodies
Antibody
ARF-1
Β-actin-HRP
FLAG-HRP
PSMA2
PSMB7
PSMD11

Company
Proteintech
Santa Cruz
Proteintech
Bethyl
Bethyl
Cell Signaling

Ref#
10790-1-AP
sc-47778
12926-1-AP
A303-816A
A303-848A
14303S
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Table 10 qRT-PCR primers
qRT-PCR Primer
Gapdh F
Gapdh R
Fbxo9 Exon 4 F
Fbxo9 Exon 4 R
Fbxo9 Exon 2-3 F
Fbxo9 Exon 2-3 R

Sequence
5’ – CAT GGC CTT CCG TGT TCC TA – 3’
5’ – CTG GTC CTC AGT GTA GCC CAA – 3’
5’ – AGA AGC TCT ATG CTG AAA GCA G – 3’
5’ – CAT CGC CCT ACG GTA GAA CT – 3’
5’ – ATG AGA GTC CGG CTG AGA GA – 3’
5’ – AGA GCT TCT TCC TGC TCT GC – 3’
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